DM

Indexes

Author Index

Åman, J. see Lodefalk, M.

Abbas, J. see Forouhi, N.G.

Abdella, N.A. see Mojiminiyi, O.A.

Acerini, C.L. Weight matters for children. A complete guide for weight, eating and fitness, 1275

Adaikalakoteswari, A., Balasubramanyam, M., Rema, M. & Mohan, V. Differential gene expression of NADPH oxidase (p22^{phox}) and hemoxygenase-1 in patients with Type 2 diabetes and microangiopathy, 666

Adamopoulos, I. see Angelopoulos, N.G.

Adang, E. see Dijkstra, R.F.

Agarwal, M.M., Dhatt, G.S. & Punnose, J. Gestational diabetes: utility of fasting plasma glucose as a screening test depends on the diagnostic criteria, 1319

Agius, E., Attard, G., Shakespeare, L., Clark, P., Vidya, M.-A., Hattersley, A.T. & Fava, S. Familial factors in diabetic nephropathy: an offspring study, 331

Aguilar-Salinas, C.A. see Navalón-García, K.

Ahmad, N. see Lawton, J.

Ahmed, A.B. see Khan, A.S.A.

Ahmed, A.T., Karter, A.J. & Liu, J. Alcohol consumption is inversely associated with adherence to diabetes self-care behaviours, 795

Ahn, C.W. see Cho, N.H.

Ahn, J.H., Kim, T.Y., Kim, Y.-J., Han, M.W., Yoon, T.H. & Chung, J.W. Lipo-prostaglandin E₁ in combination with steroid therapy is effective for treatment of sudden sensorineural hearing loss in Korean patients with Type 2 diabetes, 1339

Ahn, T.Y. see Cho, N.H.

Ajmani, A. see Vikram, N.K.

Akram, K., Pedersen-Bjergaard, U., Carstensen, B., Borch-Johnsen, K. & Thorsteinsson, B. Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a crosssectional survey, 750

Aksoy, M. see Ertugrul, M.B.

Alberti, H. see Harzallah, F.

Alberti, H. Diabetes in the Arab World, 107

Alberti, K.G.M.M. see Whincup, P.

Alberti, K.G.M.M., Zimmet, P. & Shaw, J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation, 469

Alberti, K.G.M.M., Zimmet, P. & Shaw, J. Reply, 1385

Albrechtsen, A. see Wegner, L.

Aldhahi, W.A. see Mojiminiyi, O.A.

Alem, M. see Nazir, F.S.

Ali, S., Stone, M.A., Peters, J.L., Davies, M.J. & Khunti, K. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis, 1165 Allard, S.E. see Browne, D.L.

Allard, S.E. see Wotherspoon, F.

Almdal, T. see Rosenfalck, A.M.

Amiel, S.A. see Ashwell, S.G.

Ammendola, C. see Marfella, R.

Andersen, G. see Wegner, L.

Anderson, J.M. see Porter, J.R.

Anderson, R.A., Evans, L.M., Ellis, G.R., Khan, N., Morris, K, Jackson, S.K., Rees, A., Lewis, M.J. & Frenneaux, M.P. Prolonged deterioration of endothelial dysfunction in response to postprandial lipaemia is attenuated by vitamin C in Type 2 diabetes, 258

Ando, A. see Muroi, R.

Angelopoulos, N.G., Zervas, A., Livadas, S., Adamopoulos, I., Giannopoulos, D., Goula, A. & Tolis, G. Reduced insulin secretion in normoglycaemic patients with β-thalassaemia major, 1327

Anguissola, G.B. see Pitocco, D.

Anitha, B. see Rema, M.

Anyaoku, V. see Godsland, I.F.

Araki, E. see Miyamura, N.

Arcaro, G. see Targher, G.

Argueta-Villamar, V. see Navalón-García, K.

Arun, C.S., Young, D., Batey, D., Shotton, M., Mitchie, D., Stannard, K.P. & Taylor, R. Establishing ongoing quality assurance in a retinal screening programme, 629

Ashwell, S.G., Amiel, S.A., Bilous, R.W., Dashora, U., Heller, S.R., Hepburn, D.A., Shutler, S.D., Stephens, J.W. & Home, P.D. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes, 285

Ashwell, S.G., Gebbie, J. & Home, P.D. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times, 46

Ashwell, S.G., Gebbie, J. & Home, P.D. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart, 879

Atay, A.E. see Ozmen, S.

Atkins, M. see Linnebjerg, H.

Attard, G. see Agius, E.

Averous, C. see Kessler, L.

Avierinos, J.-F. see Sejil, S.

Avignon, A. see Sultan, A.

Azizi, F. see Hosseinpanah, F.

Bacchetti, T. see Ferretti, G.

Badet, L. see Petruzzo, P.

Baek, H.S. see Park, J.H.

Bahceci, M. see Ozmen, S.

Bahr, C., Schön, S., Kuhn, J., Groop, P.H., Parkkonen, M., Wessman, M., Kleesiek, K. & Götting, C. Novel sequence variants in the human xylosyltransferase I gene and their role in diabetic nephropathy, 681

DM

Indexes

Author Index

Åman, J. see Lodefalk, M.

Abbas, J. see Forouhi, N.G.

Abdella, N.A. see Mojiminiyi, O.A.

Acerini, C.L. Weight matters for children. A complete guide for weight, eating and fitness, 1275

Adaikalakoteswari, A., Balasubramanyam, M., Rema, M. & Mohan, V. Differential gene expression of NADPH oxidase (p22^{phox}) and hemoxygenase-1 in patients with Type 2 diabetes and microangiopathy, 666

Adamopoulos, I. see Angelopoulos, N.G.

Adang, E. see Dijkstra, R.F.

Agarwal, M.M., Dhatt, G.S. & Punnose, J. Gestational diabetes: utility of fasting plasma glucose as a screening test depends on the diagnostic criteria, 1319

Agius, E., Attard, G., Shakespeare, L., Clark, P., Vidya, M.-A., Hattersley, A.T. & Fava, S. Familial factors in diabetic nephropathy: an offspring study, 331

Aguilar-Salinas, C.A. see Navalón-García, K.

Ahmad, N. see Lawton, J.

Ahmed, A.B. see Khan, A.S.A.

Ahmed, A.T., Karter, A.J. & Liu, J. Alcohol consumption is inversely associated with adherence to diabetes self-care behaviours, 795

Ahn, C.W. see Cho, N.H.

Ahn, J.H., Kim, T.Y., Kim, Y.-J., Han, M.W., Yoon, T.H. & Chung, J.W. Lipo-prostaglandin E₁ in combination with steroid therapy is effective for treatment of sudden sensorineural hearing loss in Korean patients with Type 2 diabetes, 1339

Ahn, T.Y. see Cho, N.H.

Ajmani, A. see Vikram, N.K.

Akram, K., Pedersen-Bjergaard, U., Carstensen, B., Borch-Johnsen, K. & Thorsteinsson, B. Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a crosssectional survey, 750

Aksoy, M. see Ertugrul, M.B.

Alberti, H. see Harzallah, F.

Alberti, H. Diabetes in the Arab World, 107

Alberti, K.G.M.M. see Whincup, P.

Alberti, K.G.M.M., Zimmet, P. & Shaw, J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation, 469

Alberti, K.G.M.M., Zimmet, P. & Shaw, J. Reply, 1385

Albrechtsen, A. see Wegner, L.

Aldhahi, W.A. see Mojiminiyi, O.A.

Alem, M. see Nazir, F.S.

Ali, S., Stone, M.A., Peters, J.L., Davies, M.J. & Khunti, K. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis, 1165 Allard, S.E. see Browne, D.L.

Allard, S.E. see Wotherspoon, F.

Almdal, T. see Rosenfalck, A.M.

Amiel, S.A. see Ashwell, S.G.

Ammendola, C. see Marfella, R.

Andersen, G. see Wegner, L.

Anderson, J.M. see Porter, J.R.

Anderson, R.A., Evans, L.M., Ellis, G.R., Khan, N., Morris, K, Jackson, S.K., Rees, A., Lewis, M.J. & Frenneaux, M.P. Prolonged deterioration of endothelial dysfunction in response to postprandial lipaemia is attenuated by vitamin C in Type 2 diabetes, 258

Ando, A. see Muroi, R.

Angelopoulos, N.G., Zervas, A., Livadas, S., Adamopoulos, I., Giannopoulos, D., Goula, A. & Tolis, G. Reduced insulin secretion in normoglycaemic patients with β-thalassaemia major, 1327

Anguissola, G.B. see Pitocco, D.

Anitha, B. see Rema, M.

Anyaoku, V. see Godsland, I.F.

Araki, E. see Miyamura, N.

Arcaro, G. see Targher, G.

Argueta-Villamar, V. see Navalón-García, K.

Arun, C.S., Young, D., Batey, D., Shotton, M., Mitchie, D., Stannard, K.P. & Taylor, R. Establishing ongoing quality assurance in a retinal screening programme, 629

Ashwell, S.G., Amiel, S.A., Bilous, R.W., Dashora, U., Heller, S.R., Hepburn, D.A., Shutler, S.D., Stephens, J.W. & Home, P.D. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes, 285

Ashwell, S.G., Gebbie, J. & Home, P.D. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times, 46

Ashwell, S.G., Gebbie, J. & Home, P.D. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart, 879

Atay, A.E. see Ozmen, S.

Atkins, M. see Linnebjerg, H.

Attard, G. see Agius, E.

Averous, C. see Kessler, L.

Avierinos, J.-F. see Sejil, S.

Avignon, A. see Sultan, A.

Azizi, F. see Hosseinpanah, F.

Bacchetti, T. see Ferretti, G.

Badet, L. see Petruzzo, P.

Baek, H.S. see Park, J.H.

Bahceci, M. see Ozmen, S.

Bahr, C., Schön, S., Kuhn, J., Groop, P.H., Parkkonen, M., Wessman, M., Kleesiek, K. & Götting, C. Novel sequence variants in the human xylosyltransferase I gene and their role in diabetic nephropathy, 681

Bailey, C. see Scanlon, P.H.

Bailey, C.J. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD), 109

Bain, S.C. see Dixon, A.N.

Baker, J. see Kerr, G.D.

Baktiroglu, S. see Ertugrul, M.B.

Balasubramanyam, M. see Adaikalakoteswari, A.

Balkau, B. see Cogneau, J.

Bandello, F. see Trento, M.

Banerjee, A.K. see Dixon, A.N.

Barbieri, E. see Molon, G.

Barnard, K.D., Skinner, T.C. & Peveler, R. The prevalence of comorbid depression in adults with Type 1 diabetes: systematic literature review, 445

Baron, S. see Hazard, I.

Barrett, T.G. see Porter, I.R.

Baskar, V., Venugopal, H., Holland, M.R. & Singh, B.M. Clinical utility of estimated glomerular filtration rates in predicting renal risk in a district diabetes population, 1057

Bassand, J.-P. see Schiele, F.

Batey, D. see Arun, C.S.

Batra, C.M. see Vikram, N.K.

Bednarczuk, T. see Hiromatsu, Y.

Begg, E.J. see Hughes, R.C.E.

Ben Khalifa, F. see Harzallah, F.

Benbow, S.J. see Daousi, C.

Benecchi, R. see Trento, M.

Berberoglu, K. see Ertugrul, M.B.

Berger, B., Borg, H., Fernlund, P., Stenström, G. & Sundkvist, G. Islet antibodies associated with pancreatic B-cell dysfunction at and 3 years after diagnosis of diabetes in subjects aged 35–64 years old: degree of impairment less severe than in those aged 0–34 years old, 1180

Berioli, M.G. see Celi, F.

Berthillot, C. see Petruzzo, P.

Berthold, H.K. see Gouni-Berthold, I.

Bertolini, L. see Molon, G.

Bertolini, L. see Targher, G.

Bhattarai, M.D. see Shrestha, U.K.

Bilous, R. Will ASCOT change the form of anti-hypertensive therapy?, 13

Bilous, R.W. see Ashwell, S.G.

Bilous, R.W. see New, J.P.

Bingham, C. see Edghill, E.L.

Bingley, P.J. see Castleden, H.A.J.

Bini, V. see Celi, F.

Biswas, N. see Stewart, M.W.

Bizzarri, C. see Pitocco, D.

Blaak, E.E. see Corpeleijn, E.

Blakytny, R. & Jude, E. The molecular biology of chronic wounds and delayed healing in diabetes, 594

Blonde, M.C. see Schiele, F.

Bobkiewicz-Kozłowska, T. see Dworacka, M.

Bodansky, H.J. see Feltbower, R.G.

Bodenlenz, M. see Schaller, H.C.

Boeri, C. see Kessler, L.

Bolli, G.B. see Hoogma, R.P.L.M.

Booth, G.L. see Shah, B.R.

Borch-Johnsen, K. see Akram, K.

Borch-Johnsen, K. see Wegner, L.

Borg, H. see Berger, B.

Borodulin, K., Tuomilehto, J., Peltonen, M., Lakka, T.A., Sundvall, J. & Jousilahti, P. Association of leisure time physical activity and abdominal obesity with fasting serum insulin and 2-h postchallenge plasma glucose levels, 1025

Boronat, M., Varillas, V.F., Saavedra, P., Suárez, V., Bosch, E., Carrillo, A. & Nóvoa, F.J. Diabetes mellitus and impaired glucose regulation in the Canary Islands (Spain): prevalence and associated factors in the adult population of Telde, Gran Canaria, 148

Borowska, M. see Dworacka, M.

Bosch, E. see Boronat, M.

Bosio, A. see Fornengo, P.

Bott, S., Tusek, C., Jacobsen, L.V., Endahl, L., Draeger, E., Kapitza, C. & Heise, T. Insulin determine under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes, 522

Boucher, B.J. Hypovitaminosis D and risk of Type 2 diabetes in British South Asians, 336

Boucher, B.J. Type 2 diabetes in rural and urban population: diverse prevalence and associated risk factors in Bangladesh, 450

Bouhours-Nouet, N. see Hazard, I.

Bouma, J. see Hagedoorn, M.

Boumal, D. see Schiele, F.

Bouter, K.P. see Hoogma, R.P.L.M.

Bowden, D.W. see Burdon, K.P.

Bowden, D.W., Lohman, K., Hsu, F-C., Langefeld, C.D., Carr, J.J., Lenchik, L., Wagenknecht, L.E., Freedman, B.I. & Herrington, D.M. Hormone replacement therapy is associated with increased C-reactive protein in women with Type 2 diabetes in the Diabetes Heart Study, 763

Bowker, S.L. see Johnson, J.A.

Bradshaw, D. see Levitt, N.S.

Brancato, R. see Trento, M.

Braspenning, J.C.C. see Dijkstra, R.F.

Brazert, J. see Dworacka, M.

Brink, S. see Laffel, L.M.B.

Brismar, K. see Ma, J.

Brohall, G., Odén, A. & Fagerberg, B. Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review, 609

Browne, D.L. see Wotherspoon, F.

Browne, D.L., Meeking, D.R., Allard, S.E., Munday, J.L., Shaw, K.M. & Cummings, M.H. Angiotensin II does not affect endothelial tone in Type 1 diabetes—results of a double-blind placebo controlled trial, 53

Brownstein, J.N. see Norris, S.L.

Brunetti, P. see Perriello, G.

Bruttomesso, D. see Hoogma, R.P.L.M.

Bundy, C. see Knight, K.M.

Burden, A.C. see Robertson, N.

Burden, M.L. see Robertson, N.

Burdge, G.C. see Masding, M.G.

Burdon, K.P., Langefeld, C.D., Wagenknecht, L.E., Carr, J.J., Freedman, B.I., Herrington, D. & Bowden, D.W. Association analysis of genes in the renin-angiotensin system with subclinical cardiovascular disease in families with Type 2 diabetes mellitus: The Diabetes Heart Study, 228

Busse Grawitz, A. see Slawik, M.

Butler, R.A. see Franklin, V.L.

Butzer, R. see Pfützner, J.

Buxton, M.J. see Hanney, S.R.

Buysschaert, M. see Hermans, M.P.

Cacciapuoti, F. see Marfella, R.

Cade, J.E. see Deakin, T.A.

Calangu, S. see Ertugrul, M.B.

Cameron, F.J. see Ismail, D.

Cameron, F.J. see Northam, E.A.

Campbell, F.M. see Feltbower, R.G.

Canizales-Quinteros, S. see Navalón-García, K.

Carr, J.J. see Bowden, D.W.

Carr, J.J. see Burdon, K.P.

Carrillo, A. see Boronat, M.

Carroll, A.E. & Marrero, D.G. How do parents perceive their adolescent's diabetes: a qualitative study, 1222

Carson, D.J. see Martin, R.J.L.

Carstensen, B. see Akram, K.

Casson, I.F. Pregnancy in women with diabetes—after the CEMACH report, what now?, 481

Castellani, M.S. see Celi, F.

Castleden, H.A.J., Shields, B., Bingley, P.J., Williams, A.J.K., Sampson, M., Walker, M., Gibson, J.M., McCarthy, M.I., Hitman, G.A., Levy, J.C., Hattersley, A.T., Vaidya, B. & Pearson, E.R. GAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes, 834

Cavallo, F. see Trento, M.

Cavallo, M.G. see Pitocco, D.

Cavan, D.A. see Shaban, M.C.

Celi, F., Bini, V., Papi, F., Santilli, E., Castellani, M.S., Ferretti, A., Mencacci, M., Berioli, M.G., De Giorgi, G. & Falorni, A. Circulating adipocytokines in non-diabetic and Type 1 diabetic children: relationship to insulin therapy, glycaemic control and pubertal development, 660

Chan, J.C.N. see Yang, J.K.

Chapman, P.G. see Johnson, N.A.

Chassin, L.J. see Schaller, H.C.

Chaturvedi, N. see Ferriss, J.B.

Chen, X. see Liu, L.

Cheong, H.S. see Park, K.S.

Cheong, H.S. see Shin, H.D.

Cheung, N.W. see Cutchie, W.A.

Cheung, N.W. see McLean, M.

Chien, J. see Wise, S.

Chiorazzo, G. see Marfella, R.

Chipps, D. see McLean, M.

Cho, N.H., Ahn, C.W., Park, J.Y., Ahn, T.Y., Lee, H.W., Park, T.S., Kim, I.J., Pomerantz, K., Park, C., Kimm, K.C. & Choi, D.S. Prevalence of erectile dysfunction in Korean men with Type 2 diabetes mellitus, 198

Cho, Y.M. see Park, K.S.

Cho, Y.M. see Shin, H.D.

Choi, D.S. see Cho, N.H.

Chowdhury, F.M. see Norris, S.L.

Chowdhury, T.A. see Moyes, V.

Chowdhury, T.A. Reply, 1159

Christmann, D. see Kessler, L.

Chung, J.W. see Ahn, J.H.

Cil, T. see Ozmen, S.

Cinone, F. see Marfella, R.

Cirkel, D.T. see Stewart, M.W.

Civello, D. see Stock, S.A.K.

Clark, P. see Agius, E.

Cleland, S.J. see Nazir, F.S.

Coggiola, A. see Trento, M.

Cogneau, J., Balkau, B., Weill, A., Liard, F. & Simon, D. Assessment of diabetes screening by general practitioners in France: the FPIDIA Study. 803

Colhoun, H.M. see Mulnier, H.E.

Collober-Maugeais, C. see Ristic, S.

Comte, F. see Sultan, A.

Connell, J.M.C. see Nazir, F.S.

Cook, D. see Whincup, P.

Cook, N.R. see Pradhan, A.D.

Coppini, D.V., Spruce, M.C., Thomas, P. & Masding, M.G. Established diabetic neuropathy seems irreversible despite improvements in metabolic and vascular risk markers—a retrospective case—control study in a hospital patient cohort, 1016

Coppola, L. see Marfella, R.

Cornel, M.C. see van Esch, S.C.M.

Corpeleijn, E., van der Kallen, C.J.H., Kruijshoop, M., Magagnin, M.G.P., de Bruin, T.W.A., Feskens, E.J.M., Saris, W.H.M. & Blaak, E.E. Direct association of a promoter polymorphism in the CD36/FAT fatty acid transporter gene with Type 2 diabetes mellitus and insulin resistance, 907

Corwin, P.A. see Gill, E.A.

Costa, A. see Molon, G.

Coutant, R. see Hazard, I.

Craig, D. see Nelson, E.A.

Craig, D. see O'Meara, S. Cressier, F. see Ristic, S.

Crinò, A. see Pitocco, D.

Croom, A. see Moyes, V.

Crowle, T. see Sampson, M.J.

Cummings, M.H. see Browne, D.L. Cummings, M.H. see Wotherspoon, F.

Currie, C.J. see Morgan, C.Ll.

Currie, C.J. Diabetes prevalence in England, 2001, 1268

Cutchie, W.A., Cheung, N.W. & Simmons, D. Comparison of international and New Zealand guidelines for the care of pregnant women with diabetes, 460

de la Calle, H. see Hoogma, R.P.L.M.

de la Peña, A. see Linnebjerg, H.

Díaz-Vargas, M.E. see Navalón-García, K.

D'Andrea, F. see Marfella, R.

Dahlquist, G. see Ma, J.

Dai, M. see Jian, W.-X.

Dalamanga, E.G. see Karamitsos, T.D.

Dalton, J. see Nelson, E.A.

Dalton, J.E. see O'Meara, S.

Daly, M.E., Paisey, R., Paisey, R., Millward, B.A., Eccles, C., Williams, K., Hammersley, S., MacLeod, K.M. & Gale, T.J. Short-term effects of severe dietary carbohydrate-restriction advice in Type 2 diabetes—a randomized controlled trial, 15

Damm, P. see Nielsen, L.R.

Daousi, C., Benbow, S.J., Woodward, A. & MacFarlane, I.A. The natural history of chronic painful peripheral neuropathy in a community diabetes population, 1021 Dasgupta, I. see New, J.P.

Dashora, U. see Ashwell, S.G.

Daures, J.P. see Sultan, A.

Davidson, M., Zhu, J., Lu, W., Tracy, R.P., Robbins, D.C., Resnick, H.E., Ruotolo, G. & Howard, B.V., and the Strong Heart Study Investigators. Plasminogen activator inhibitor-1 and the risk of Type 2 diabetes mellitus in American Indians: the Strong Heart Study, 1158

Davies, M., Dempster, M. & Malone, A. Do people with diabetes who need to talk want to talk?, 917

Davies, M.J. see Ali, S.

de Bruin, T.W.A. see Corpeleijn, E.

de Fine Olivarius, N. & Jørgensen, L.G.M. Near-patient blood glucose measurements should only be used alone in the diagnosis of diabetes in cases of high glucose concentrations, 1042

De Giorgi, G. see Celi, F.

Deakin, T.A., Cade, J.E., Williams, R. & Greenwood, D.C. Structured patient education: the Diabetes X-PERT Programme makes a difference, 944

Dean, J.D. see Young, B.

Deary, I.J. see McAulay, V.

Deepa, R. see Mohan, V.

Deepa, R. see Rema, M.

Delcourt, I. see Tauveron, I.

Dempsey, E. see Gerstein, H.C.

Dempster, M. see Davies, M.

Desbiez, F. see Tauveron, I.

Descotes-Genon, V. see Schiele, F.

DeVane, J. see Jaffe, R.

DeVries, J.H. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK: Response to Roze et al., 709

Dhatariya, K. see Sampson, M.J.

Dhatt, G.S. see Agarwal, M.M.

Di Pietro, C. see Perriello, G.

Di Stasio, E. see Pitocco, D.

Didangellos, T.P. see Karamitsos, T.D.

Dijkstra, R.F., Niessen, L.W., Braspenning, J.C.C., Adang, E. & Grol, R.T.P.M. Patient-centred and professional-directed implementation strategies for diabetes guidelines: a clusterrandomized trial-based cost-effectiveness analysis, 164

Dixon, A.N., Jude, E.B., Banerjee, A.K. & Bain, S.C. Simultaneous pulmonary and cerebral oedema, and multiple CNS infarctions as complications of diabetic ketoacidosis: a case report, 571

Donaldson, J. see Stewart, M.W.

Donath, S.M. see Ismail, D.

Doney, A.S.F. see Donnelly, L.A.

Donnelly, L.A., Doney, A.S.F., Hattersley, A.T., Morris, A.D. & Pearson, E.R. The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes, 128

Donovan, J. see Godsland, I.F.

Dorel, S.B. see Petruzzo, P.

Dornan, T. see Knight, K.M.

Doughty, R.N. see Kerr, G.D.

Douglas, M. see Lawton, J.

Dozio, N. see Sampson, M.J.

Draeger, E. see Bott, S.

Driver, R. see Moyes, V.

Duncan, E. see Toh, V.

Duncan, G. see Shotliff, K.P.

Dunseath, G. see Peter, R.

Dworacka, M., Wender-Ożegowska, E., Winiarska, H., Borowska, M., Zawiejska, A., Pietryga, M., Brazert, J., Szczawinska, K. & Bobkiewicz-Kozłowska, T. Plasma anhydro-D-glucitol (1,5-AG) as an indicator of hyperglycaemic excursions in pregnant women with diabetes, 171

Eagle, A.R.R. see Wolford, J.K.

Ecarnot, F. see Schiele, F.

Eccles, C. see Daly, M.E.

Edghill, E.L., Bingham, C., Slingerland, A.S., Minton, J.A.L., Noordam, C., Ellard, S. & Hattersley, A.T. Hepatocyte nuclear factor-1 beta mutations cause neonatal diabetes and intrauterine growth retardation: support for a critical role of HNF-1β in human pancreatic development, 1301

Edwards, A. see Johnson, J.A.

Edwards, J. see Porter, J.R.

Efendic, S. see Ma, J.

Eher, R. see Maier, C.

Eisenhut, M. Interleukin-1 and the constellation of pulmonary oedema, and cerebral infarctions and oedema in diabetic ketoacidosis. 1386

El Gebely, S.A. see Mojiminiyi, O.A.

Elkeles, R.S. see Godsland, I.F.

Ellard, S. see Edghill, E.L.

Ellard, S. see Porter, J.R.

Ellepola, A.N.B. see Soysa, N.S.

Ellis, G.R. see Anderson, R.A.

Ellis, J.D. see Leese, G.P.

Endahl, L. see Bott, S.

English, D.R. see Hodge, A.M.

Epifani, G. see Fornengo, P.

Eriksson, J.G. see Mager, U.

Ernest II, C.S. see Linnebjerg, H.

Ertugrul, M.B., Baktiroglu, S., Salman, S., Unal, S., Aksoy, M., Berberoglu, K. & Calangu, S. The diagnosis of osteomyelitis of the foot in diabetes: microbiological examination vs. magnetic resonance imaging and labelled leucocyte scanning, 649

Evans, L.M. see Anderson, R.A.

Fagerberg, B. see Brohall, G.

Falezza, G. see Targher, G.

Falhammar, H. see Ma, J.

Falorni, A. see Celi, F. Fang, Q. see Hu, C.

Farjadian, S. see Mojtahedi, Z.

Farmer, A., Kinmonth, A.-L. & Sutton, S. Measuring beliefs about taking hypoglycaemic medication among people with Type 2 diabetes, 265

Faust, M. see Gouni-Berthold, I.

Fava, S. see Agius, E.

Feher, M.D. see Godsland, I.F.

Feltbower, R.G., Campbell, F.M., Bodansky, H.J., Stephenson, C.R. & McKinney, P.A. Insulin pump therapy in childhood diabetes cost implications for Primary Care Trusts, 86

Feng, Y. see Yang, J.K.

Ferguson, B. see Forouhi, N.

Ferguson, B.A. see Forouhi, N.G.

Ferguson, S.C. & Frier, B.M. Hippocampal volume and cognitive performance in long-standing Type 1 diabetic patients without macrovascular complications, 1271

Fernlund, P. see Berger, B.

Ferretti, A. see Celi, F.

Ferretti, G., Bacchetti, T., Rabini, R.A., Vignini, A., Nanetti, L., Moroni, C. & Mazzanti, L. Homocysteinylation of low-density lipoproteins (LDL) from subjects with Type 1 diabetes: effect on oxidative damage of human endothelial cells, 808

Ferriss, J.B., Webb, D., Chaturvedi, N., Fuller, J.H. & Idzior-Walus, B.; The EURODIAB Prospective Complications Group. Weight gain is associated with improved glycaemic control but with adverse changes in plasma lipids and blood pressure in Type 1 diabetes, 557

Feskens, E.J.M. see Corpeleijn, E.

Fichter, L. see Toh, V.

Fisher, B.M. see Mukhopadhyay, B.

Fisher, M. Diabetes and Cardiovascular Disease, 929

Flather, M.D. see Godsland, I.F.

Fornengo, P., Bosio, A., Epifani, G., Pallisco, O., Mancuso, A. & Pascale, C. Prevalence of silent myocardial ischaemia in newonset middle-aged Type 2 diabetic patients without other cardiovascular risk factors, 775

Forouhi, N., Goyder, E., Merrick, D., Wild, S. & Ferguson, B. Authors' reply, 1268

Forouhi, N.G. see Mukhopadhyay, B.

Forouhi, N.G., Merrick, D., Goyder, E., Ferguson, B.A., Abbas, J., Lachowycz, K. & Wild, S.H. Diabetes prevalence in England, 2001—estimates from an epidemiological model, 189

Forsblom, C. see Turunen, J.A.

Forst, S. see Pfützner, J.

Forst, T. see Pfützner, J.

Fosbury, J. see Shaban, M.C.

Frame, I. see Hanney, S.R.

Franklin, V.L., Waller, A., Pagliari, C. & Greene, S.A. A randomized controlled trial of Sweet Talk, a text-messaging system to support young people with diabetes, 1332

Franklin, V.L., Wilson, A.W., Butler, R.A. & Greene, S.A. A predictive tool for the self-management of diabetes (Librae): evaluation using a continuous glucose monitoring system, 21

Fraser, L. see Ismail, D.

Frayling, T.M. see Porter, J.R.

Freed, M.I. see Viberti, G.

Freedman, B.I. see Bowden, D.W.

Freedman, B.I. see Burdon, K.P.

Frenneaux, M.P. see Anderson, R.A.

Frier, B.M. see Ferguson, S.C.

Frier, B.M. see Geddes, J.

Frier, B.M. see McAulay, V.

Fu, H.J. see Yang, J.K.

Fujita, N. see Muroi, R.

Fukutani, T. see Hiromatsu, Y.

Fuller, J.H. see Ferriss, J.B.

Furuseth, K. see Stewart, M.W.

Götting, C. see Bahr, C.

Gaboury, I. see Malcolm, J.C.

Gala, J.-L. see Hermans, M.P.

Gale, T.J. see Daly, M.E.

Gall, M-A. see Kølendorf, K.

Gamble, G.D. see Kerr, G.D.

Gardiner, S.J. see Hughes, R.C.E.

Garvey, W.T. see Lyons, T.J.

Gatelais, F. see Hazard, I.

Gaudias, J. see Kessler, L.

Gebbie, J. see Ashwell, S.G.

Gebert, R. see Ismail, D.

Geddes, J., McGeough, E. & Frier, B.M. Young adults with Type 1 diabetes in tertiary education: do students receive adequate specialist care?, 1155

Gerhard-Herman, M.D. see Raji, A.

Gerstein, H.C., Yale, J.-F., Harris, S.B., Issa, M., Stewart, J.A. & Dempsey, E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study, 736

Ghaderi, A. see Mojtahedi, Z.

Giannakidou, E. see Gouni-Berthold, I.

Giannopoulos, D. see Angelopoulos, N.G.

Gibson, J.M. see Castleden, H.A.J.

Giles, G.G. see Hodge, A.M.

Gilg, J. see Whincup, P.

Gill, E.A., Corwin, P.A., Mangin, D.A. & Sutherland, M.G. Diabetes care in rest homes in Christchurch, New Zealand, 1252

Gill, G. see Woodward, A.

Giorda, C., Petrelli, A. & Gnavi, R., the Regional Board for Diabetes Care of Piemonte. The impact of second-level specialized care on hospitalization in persons with diabetes: a multilevel populationbased study, 377

Glümer, C. see Wegner, L.

Gloyn, A.L. see Porter, J.R.

Gnavi, R. see Giorda, C.

Godsland, I.F., Elkeles, R.S., Feher, M.D., Nugara, F., Rubens, M.B., Richmond, W., Khan, M., Donovan, J., Anyaoku, V. & Flather, M.D., for the PREDICT Study Group. Coronary calcification, homocysteine, C-reactive protein and the metabolic syndrome in Type 2 diabetes: the Prospective Evaluation of Diabetic Ischaemic Heart Disease by Coronary Tomography (PREDICT) Study, 1192

Goh, S.K. see Lim, S.C.

Gokulakrishnan, K. see Mohan, V.

Golder, S. see Nelson, E.A.

Golder, S. see O'Meara, S.

Gomis, R. see Hoogma, R.P.L.M.

González-Chávez, A. see Navalón-García, K.

Gough, S.C. see Palin, S.L.

Goula, A. see Angelopoulos, N.G.

Gouni-Berthold, I., Giannakidou, E., Faust, M., Berthold, H.K. & Krone, W. Association of the promoter polymorphism –232C/G of the phosphoenolpyruvate carboxykinase gene (PCK1) with Type 2 diabetes mellitus, 419

Goyder, E. see Forouhi, N.

Goyder, E. see Forouhi, N.G.

Gram, J. see Heldgaard, P.E.

Grant, I. see Nyirenda, M.J.

Grant, J. see Hanney, S.R.



Gravenor, M.B. see Pegge, N.C.

Green, P. see Hanney, S.R.

Greene, S.A. see Franklin, V.L.

Greenwood, D.C. see Deakin, T.A.

Greenwood, R.H. see Sampson, M.J.

Griffin, S.J. see Heldgaard, P.E.

Grol, R.T.P.M. see Dijkstra, R.F.

Groop, P.H. see Bahr, C.

Groop, P-H. see Turunen, J.A.

Gu, H.F. see Ma, J.

Gu, Y .- Y . see Jian, W .- X .

Guglielmi, C. see Pitocco, D.

Gupta, N. see Vikram, N.K.

Häger, S. see von Sengbusch, S.

Hämäläinen, H. see Mager, U.

Haan, M.N. see Pradhan, A.D.

Habib, G. see Seiil, S.

Haffner, S. see Viberti, G.

Hagedoorn, M., Keers, J.C., Links, T.P., Bouma, J., Ter Maaten, J.C. & Sanderman, R. Improving self-management in insulintreated adults participating in diabetes education. The role of overprotection by the partner, 271

Hallowell, N. see Lawton, J.

Hamada, Y. see Watarai, A.

Hamaguchi, T. see Satani, K.

Hamajima, N. see Watarai, A.

Hamann, A. see Stewart, M.W.

Hammersley, S. see Daly, M.E.

Hammond, P.J. see Hoogma, R.P.L.M.

Han, B.G. see Park, K.S.

Han, B.G. see Shin, H.D.

Han, J.-F. see Jian, W.-X.

Han, M.W. see Ahn, J.H.

Hanifi-Moghaddam, P., Kappler, S., Seissler, J., Müller-Scholze, S.,
 Martin, S., Roep, B.O., Strassburger, K., Kolb, H. & Schloot,
 N.C. Altered chemokine levels in individuals at risk of Type 1
 diabetes mellitus, 156

Hanna, L. see Lawton, J.

Hanney, S.R., Home, P.D., Frame, I., Grant, J., Green, P. & Buxton, M.J. Identifying the impact of diabetes research, 176

Hansen, T. see Wegner, L.

Hansmann, Y. see Kessler, L.

Hanson, R.L. see Wolford, J.K.

Hara, T. see Tsutsumi, Y.

Harper, C.A. see Phiri, R.

Harris, S.B. see Gerstein, H.C.

Harten-Ash, V. Repeat education with self-monitoring of blood glucose improves HbA_{1c}, 220

Harzallah, F., Alberti, H. & Ben Khalifa, F. The metabolic syndrome in an Arab population: a first look at the new International Diabetes Federation criteria, 441

Hasegawa, Y. see Satani, K.

Hatazaki, M. see Nakatani, Y.

Hattersley, A.T. see Agius, E.

Hattersley, A.T. see Castleden, H.A.J.

Hattersley, A.T. see Donnelly, L.A.

Hattersley, A.T. see Edghill, E.L.

Hattersley, A.T. see Porter, J.R.

Hattersley, A.T. see Stenhouse, E.

Hawthorne, G. Metformin use and diabetic pregnancy—has its time come?, 223

Hazard, I., Bouhours-Nouet, N., Baron, S., Ramos, E., Gatelais, F. & Coutant, R. Birthweight predicts insulin requirements in children and adolescents with Type 1 diabetes, 1273

He, K. see Song, Y.

Hearnshaw, H. & Lindenmeyer, A. What do we mean by adherence to treatment and advice for living with diabetes? A review of the literature on definitions and measurements, 720

Heise, M.A. see Viberti, G.

Heise, T. see Bott, S.

Heldgaard, P.E. & Griffin, S.J. Routinely collected general practice data aids identification of people with hyperglycaemia and metabolic syndrome, 996

Heldgaard, P.E., Sidelmann, J.J., Hindsberger, C., Olivarius, N. de F., Henriksen, J.E. & Gram, J. Relationship of glucose concentrations with PAI-1 and t-PA in subjects with normal glucose tolerance, 887

Heller, S.R. see Ashwell, S.G.

Heller, S.R. see Kølendorf, K.

Hendrix, S.L. see Pradhan, A.D.

Henriksen, J.E. see Heldgaard, P.E.

Hepburn, D.A. see Ashwell, S.G.

Herman, W.H. see Viberti, G.

Hermans, M.P., Gala, J.-L. & Buysschaert, M. The MTHFR C₆₇₇T polymorphism confers a high risk for stroke in both homozygous and heterozygous T allele carriers with Type 2 diabetes, 529

Herrington, D. see Burdon, K.P.

Herrington, D.M. see Bowden, D.W.

Heyburn, P.J. see Sampson, M.J.

Hilsted, J. see Rosenfalck, A.M.

Hindsberger, C. see Heldgaard, P.E.

Hiort, O. see von Sengbusch, S.

Hiromatsu, Y., Mukai, T., Kaku, H., Miyake, I., Ichimura, M., Fukutani, T., Nakayama, H., Takata, K., Imamura, Y., Shoji, S., Yamada, K., Koda, Y. & Bednarczuk, T. IL-18 gene polymorphism confers susceptibility to the development of anti-GAD65 antibody in Graves' disease, 211

Hitchman, R. see McElduff, A.

Hitman, G.A. see Castleden, H.A.J.

Hjemdahl, P. see Yngen, M.

Hodge, A.M., English, D.R., O'Dea, K. & Giles, G.G. Alcohol intake, consumption pattern and beverage type, and the risk of Type 2 diabetes, 690

Holland, M.R. see Baskar, V.

Holland, P. see Milton, B.

Holman, R. see Viberti, G.

Home, P.D. see Ashwell, S.G.

Home, P.D. see Hanney, S.R.

Home, P.D. Cost-effectiveness of CSII, 707

Hoogma, R.P.L.M., Hammond, P.J., Gomis, R., Kerr, D., Bruttomesso, D., Bouter, K.P., Wiefels, K.J., de la Calle, H., Schweitzer, D.H., Pfohl, M., Torlone, E., Krinelke, L.G. & Bolli, G.B., on behalf of the 5-Nations Study Group. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations

Horsley, T. see Norris, S.L.

Hosseinpanah, F., Rambod, M., Reza Ghaffari, H.R. & Azizi, F. Predicting isolated postchallenge hyperglycaemia: a new approach; Tehran Lipid and Glucose Study (TLGS), 982

Hovorka, R. see Schaller, H.C.

Hovorka, R. Continuous glucose monitoring and closed-loop systems, 1

Howard, B.V. see Davidson, M.

Hsu, F-C. see Bowden, D.W.

Hu, C., Jia, W., Fang, Q., Zhang, R., Wang, C., Lu, J. & Xiang, K. Peroxisome proliferator-activated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects, 1307

Huang, C. see Liu, L.

Huang, G. see Zhang, D.

Hughes, R.C.E. & Rowan, J.A. Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome?, 318

Hughes, R.C.E., Gardiner, S.J., Begg, E.J. & Zhang, M. Effect of pregnancy on the pharmacokinetics of metformin, 323

Hundborg, H.H. see Kruse, A.

Hussain, A. Reply, 450

Hux, J.E. see Shah, B.R.

Hykin, P. see Scanlon, P.H.

Ichihara, Y. see Miyamura, N.

Ichimura, M. see Hiromatsu, Y.

Ideno, J. see Muroi, R.

IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care, 579

Idzior-Walus, B. see Ferriss, J.B.

Iglesias, C. see Nelson, E.A.

Iglesias, C. see O'Meara, S.

Ihara, K. see Tsutsumi, Y.

Ilanne-Parikka, P. see Mager, U.

Imamura, Y. see Hiromatsu, Y.

Insacco, C. see Trento, M.

Ishay, A., Lavi, I. & Luboshitzky, R. Prevalence and risk factors for asymptomatic bacteriuria in women with Type 2 diabetes mellitus, 185

Ishibashi, S. see Muroi, R.

Ishikawa, T. see Satani, K.

Ismail, D., Gebert, R., Vuillermin, P.J., Fraser, L., McDonnell, C.M., Donath, S.M. & Cameron, F.J. Social consumption of alcohol in adolescents with Type 1 diabetes is associated with increased glucose lability, but not hypoglycaemia, 830

Ismail, H., Wright, J., Rhodes, P. & Scally, A. Quality of care in diabetic patients attending routine primary care clinics compared with those attending GP specialist clinics, 851

Issa, M. see Gerstein, H.C.

Jørgensen, L.G.M. see de Fine Olivarius, N.

Jørgensen, T. see Wegner, L.

Jack Jr, L. see Norris, S.L.

Jackson, S.K. see Anderson, R.A.

Jacobsen, L.V. see Bott, S.

Jacobsen, P. see Lajer, M.

Jaffe, R., Mani, J., DeVane, J. & Mani, H. Tolerance loss in diabetics: association with foreign antigen exposure, 924

Jakobsen, P. see Mortensen, U.M.

James, W.H. The sex ratios of offspring of diabetic parents, 1043 Janand-Delenne, B. see Sejil, S.

Janghorbani, M., Stenhouse, E.A., Jones, R.B. & Millward, B.A. Is neighbourhood deprivation a risk factor for gestational diabetes mellitus?, 313

Jeffcoate, W.J. The evidence base to guide the use of antibiotics in foot ulcers in people with diabetes is thin, but what are we going to do about it?, 339

Jendle, J. see Kølendorf, K.

Jenkins, A.J. see Lyons, T.J.

Jensen, B.S. see Mortensen, U.M.

Jerums, G. see Thomas, M.C.

Jia, W. see Hu, C.

Jian, W.-X., Luo, T.-H., Gu, Y.-Y., Zhang, H.-L., Zheng, S., Dai, M., Han, J.-F., Zhao, Y., Li, G. & Luo, M. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population, 967

Jie, X. see Tsutsumi, Y.

Jin, F. see Sun, L.

Jing, P. see Zhang, D.

Johnson, E. see Scanlon, P.H.

Johnson, J.A., Majumdar, S.R., Bowker, S.L., Toth, E.L. & Edwards, A. Self-monitoring in Type 2 diabetes: a randomized trial of reimbursement policy, 1247

Johnson, K.C. see Pradhan, A.D.

Johnson, N.A., Stannard, S.R., Rowlands, D.S., Chapman, P.G., Thompson, C.H., Sachinwalla, T. & Thompson, M.W. Shortterm suppression of plasma free fatty acids fails to improve insulin sensitivity when intramyocellular lipid is elevated, 1061

Jones, C. see Sampson, M.J.

Jones, N.P. see Viberti, G.

Jones, R.B. see Janghorbani, M.

Jousilahti, P. see Borodulin, K.

Jude, E. see Blakytny, R.

Jude, E.B. see Dixon, A.N.

Jung, R.T. see Leese, G.P.

Kølendorf, K., Ross, G.P., Pavlic-Renar, I., Perriello, G., Philotheou, A., Jendle, J., Gall, M-A. & Heller, S.R. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes, 729

Kahn, S.E. see Viberti, G.

Kakishita, E. see Satani, K.

Kaku, H. see Hiromatsu, Y.

Kamiya, H. see Watarai, A.

Kanemitsu, S. see Tsutsumi, Y.

Kaneto, H. see Nakatani, Y.

Kapitza, C. see Bott, S.

Kappler, S. see Hanifi-Moghaddam, P.

Karamitsos, D.T. see Karamitsos, T.D.

Karamitsos, T.D., Karvounis, H.I., Didangellos, T.P.,

Papadopoulos, C.E., Dalamanga, E.G., Karamitsos, D.T., Parharidis, G.E. & Louridas, G.E. Usefulness of colour tissue Doppler imaging in assessing aortic elastic properties in Type 1 diabetic patients, 1201

Karter, A.J. see Ahmed, A.T.

Karvounis, H.I. see Karamitsos, T.D.

Kasper, J. see Lenz, M.

Katsuno, T. see Satani, K.

Kawamori, D. see Nakatani, Y.

Keeffe, J.E. see Phiri, R.

Keely, E. see Malcolm, J.C.

Keers, J.C. see Hagedoorn, M.

Keightley, S. see Scanlon, P.H.

Keinänen-Kiukaanniemi, S. see Mager, U.

Kerr, D. & Richardson, T. Treating insulin allergy with continuous subcutaneous insulin infusion (CSII), 1159

Kerr, D. see Hoogma, R.P.L.M.

Kerr, D. see Shaban, M.C.

Kerr, G.D., Gamble, G.D., Doughty, R.N., Simmons, D. & Baker, J. Mortality in individuals with Type 2 diabetes and heart disease in a unique New Zealand population, 1313

Kessler, L., Piemont, Y., Ortega, F., Lesens, O., Boeri, C., Averous, C., Meyer, R., Hansmann, Y., Christmann, D., Gaudias, J. & Pinget, M. Comparison of microbiological results of needle puncture vs. superficial swab in infected diabetic foot ulcer with osteomyelitis, 99

Kesson, C.M. see Mukhopadhyay, B.

Khan, A.S.A., McLoughney, C.R. & Ahmed, A.B. The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes, 1079

Khan, M. see Godsland, I.F.

Khan, N. see Anderson, R.A.

Khunti, K. see Ali, S.

Kilpikari, R. see Turunen, J.A.

Kim, H.T. see Park, K.S.

Kim, H.T. see Shin, H.D.

Kim, I.J. see Cho, N.H.

Kim, J.H. see Park, J.H.

Kim, J.W. see Shin, H.D.

Kim, T.Y. see Ahn, J.H.

Kim, W.H. see Park, J.H.

Kim, Y.-J. see Ahn, J.H.

Kim, Y.J. see Shin, H.D.

Kimm, K. see Park, K.S.

Kimm, K. see Shin, H.D.

Kimm, K.C. see Cho, N.H.

Kinmonth, A.-L. see Farmer, A.

Kleesiek, K. see Bahr, C.

Klein, R.L. see Lyons, T.J.

Knight, K.M., Dornan, T. & Bundy, C. The diabetes educator: trying hard, but must concentrate more on behaviour, 485

Knowler, W.C. see Wolford, J.K.

Knudsen, L.L. see Kruse, A.

Kobayashi, H. see Muroi, R.

Kobayashi, Y. see Watarai, A.

Koda, Y. see Hiromatsu, Y.

Koh, A. see Lim, S.C.

Koh, I. see Shin, H.D.

Kohri, K. see Satani, K.

Kolb, H. see Hanifi-Moghaddam, P.

Kolm, P. see Rhee, M.K.

Konya, H. see Satani, K.

Kothare, P.A. see Linnebjerg, H.

Krömeke, O. see Lobnig, B.M.

Kravitz, B. see Viberti, G.

Krinelke, L.G. see Hoogma, R.P.L.M.

Krone, W. see Gouni-Berthold, I.

Kruijshoop, M. see Corpeleijn, E.

Kruse, A., Thomsen, R.W., Hundborg, H.H., Knudsen, L.L., Sørensen, H.T. & Schønheyder, H.C. Diabetes and risk of acute infectious conjunctivitis—a population-based case-control study,

Kuhn, J. see Bahr, C.

Kuo, T.B.J. see Sun, T.B.

Laakso, M. see Mager, U.

Labastie, N. see Sejil, S.

Lachin, J. see Viberti, G.

Lachowycz, K. see Forouhi, N.G.

Lackland, D.T. see Lyons, T.J.

LaCroix, A.Z. see Pradhan, A.D.

Laffel, L.M.B., Wentzell, K., Loughlin, C., Tovar, A., Moltz, K. & Brink, S. Sick day management using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: a randomized clinical trial, 278

Lai, M.-Y. see Su, D.-H.

Lai, Y.R. see Lim, S.C.

Laight, D.W. see Wotherspoon, F.

Lajer, M., Schjoedt, K.J., Jacobsen, P., Tarnow, L. & Parving, H.-H. Aldosterone synthase (CYP11B2) -344T/C polymorphism is not associated with the initiation and progression of diabetic nephropathy in Caucasian Type 1 diabetic patients, 675

Lakka, T.A. see Borodulin, K.

Langefeld, C.D. see Bowden, D.W.

Langefeld, C.D. see Burdon, K.P.

Lassmann-Vague, V. see Sejil, S.

Lattanzio, R. see Trento, M.

Laupacis, A. see Shah, B.R.

Lauterbach, K.W. see Stock, S.A.K.

Lavi, I. see Ishay, A.

Laville, M. see Petruzzo, P.

Lawrenson, R.A. see Mulnier, H.E.

Lawson, M.L. see Malcolm, J.C.

Lawton, J., Ahmad, N., Hanna, L., Douglas, M. & Hallowell, N. Diabetes service provision: a qualitative study of the experiences and views of Pakistani and Indian patients with Type 2 diabetes, 1003

Leary, S.D. see Shultis, W.A.

Lee, B.L. see Lim, S.C.

Lee, H.K. see Park, K.S.

Lee, H.K. see Shin, H.D.

Lee, H.W. see Cho, N.H. Lee, J.-K. see Park, K.S.

Lee, J.-K. see Shin, H.D.

Lee, J.-Y. see Park, K.S.

Lee, J.-Y. see Shin, H.D.

Lees, K.R. see Nazir, F.S.

Leese, G.P., Morris, A.D., Petrie, J., Jung, R.T. & Ellis, J.D. Reply,

Lefrançois, N. see Petruzzo, P.

Legalery, P. see Schiele, F.

Lenchik, L. see Bowden, D.W.

Lenz, M., Kasper, J. & Mühlhauser, I. Searching for diabetes decision aids and related background information, 912

Lesens, O. see Kessler, L.

Leslie, E. see Xu, F.

Levitan, E.B. see Song, Y.

Levitt, N.S. & Bradshaw, D. The impact of HIV/AIDS on Type 2 diabetes prevalence and diabetes healthcare needs in South Africa: projections for 2010, 103

Levy, J.C. see Castleden, H.A.J.

Lewis, M.J. see Anderson, R.A.

Lewis, N. see Toh, V.

Li, G. see Jian, W.-X.

Li, L. see Zhang, D.

Li, X. see Sundquist, K.

Liard, F. see Cogneau, J.

Liberti, D. see Marfella, R.

Lim, S.C., Goh, S.K., Lai, Y.R., Tee, W.W., Koh, A., Xu, X.H., Wu, Y.S., Yap, E., Subramaniam, T. & Sum, C.F. Relationship between common functional polymorphisms of the p22phox gene (-930A > G and +242C > T) and nephropathy as a result of Type 2 diabetes in a Chinese population, 1037

Lim, S.C., Tan, H.H., Goh, S.K., Subramaniam, T., Sum, C.F., Tan, I.K., Lee, B.L. & Ong, C.N. Oxidative burden in prediabetic and diabetic individuals: evidence from plasma coenzyme Q10,

Lindenmeyer, A. see Hearnshaw, H.

Lindi, V. see Mager, U.

Lindström, J. see Mager, U.

Links, T.P. see Hagedoorn, M.

Linnebjerg, H., Kothare, P.A., Skrivanek, Z., de la Peña, A., Atkins, M., Ernest II, C.S. & Trautmann, M.E. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes, 240

Liu, J. see Ahmed, A.T.

Liu, L., Yu, Q., Wang, H., Zhang, S.X., Huang, C. & Chen, X. Association of intercellular adhesion molecule 1 polymorphisms with retinopathy in Chinese patients with Type 2 diabetes, 643

Liu, S. see Song, Y. Livadas, S. see Angelopoulos, N.G.

Lobnig, B.M. & Wolf, O.T. Reply, 1272

Lobnig, B.M., Krömeke, O., Optenhostert-Porst, C. & Wolf, O.T. Hippocampal volume and cognitive performance in longstanding Type 1 diabetic patients without macrovascular complications, 32

Lodefalk, M. & Åman, J. Food habits, energy and nutrient intake in adolescents with Type 1 diabetes mellitus, 1225

Lohman, K. see Bowden, D.W.

Lopes-Virella, M. see Lyons, T.J.

Lough, G. see Malcolm, J.C.

Loughlin, C. see Laffel, L.M.B.

Louridas, G.E. see Karamitsos, T.D.

Lu, J. see Hu, C.

Lu, W. see Davidson, M.

Luboshitzky, R. see Ishay, A.

Lucassen, P.L.B.J. see van de Laar, F.A.

Luger, A. see Maier, C.

Luo, M. see Jian, W.-X.

Luo, T.-H. see Jian, W.-X.

Luzio, S.D. see Peter, R.

Lyons, T.J., Jenkins, A.J., Zheng, D., Klein, R.L., Otvos, J.D., Yu, Y., Lackland, D.T., McGee, D., McHenry, M.B., Lopes-Virella, M. & Garvey, W.T., The DCCT/EDIC Research Group, Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness, 955

Möllsten, A. see Ma, J.

Mühlhauser, I. see Lenz, M.

Müller, C. see Nielsen, L.R.

Müller-Godeffroy, E. see von Sengbusch, S.

Müller-Scholze, S. see Hanifi-Moghaddam, P.

Ma, J., Möllsten, A., Prázny, M., Falhammar, H., Brismar, K., Dahlquist, G., Efendic, S. & Gu, H.F. Genetic influences of the intercellular adhesion molecule 1 (ICAM-1) gene polymorphisms in development of Type 1 diabetes and diabetic nephropathy, 1093

MacFarlane, I.A. see Daousi, C.

MacIsaac, R. see Thomas, M.C.

MacLeod, K.M. see Daly, M.E.

Madhu, S.V. see Vikram, N.K.

Madsbad, S. see Rosenfalck, A.M.

Magagnin, M.G.P. see Corpeleijn, E.

Mager, U., Lindi, V., Lindström, J., Eriksson, J.G., Valle, T.T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Tuomilehto, J., Laakso, M., Pulkkinen, L. & Uusitupa, M. for the Finnish Diabetes Prevention Study Group. Association of the Leu72Met polymorphism of the ghrelin gene with the risk of Type 2 diabetes in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study, 685

Maier, C., Mustapic, D., Schuster, E., Luger, A. & Eher, R. Effect of a pocket-size tablet-dispensing device on glycaemic control in Type 2 diabetic patients, 40

Majumdar, S.R. see Johnson, J.A.

Malcolm, J.C., Lawson, M.L., Gaboury, I., Lough, G. & Keely, E. Glucose tolerance of offspring of mother with gestational diabetes mellitus in a low-risk population, 565

Malone, A. see Davies, M.

Malone, J.K. see Roach, P.

Mancuso, A. see Fornengo, P.

Manfrini, S. see Pitocco, D.

Mangin, D.A. see Gill, E.A.

Mani, H. see Jaffe, R. Mani, J. see Jaffe, R.

Manson, J.E. see Pradhan, A.D.

Manson, J.E. see Song, Y.

Marchese, F. see Marfella, R.

Marfella, M.A. see Marfella, R.

Marfella, R., Cacciapuoti, F., Siniscalchi, M., Sasso, F.C., Marchese, F., Cinone, F., Musacchio, E., Marfella, M.A., Ruggiero, L., Chiorazzo, G., Liberti, D., Chiorazzo, G., Nicoletti, G.F., Saron, C., D'Andrea, F., Ammendola, C., Verza, M. & Coppola, L. Effect of moderate red wine intake on cardiac prognosis after recent acute myocardial infarction of subjects with Type 2 diabetes mellitus, 974

Mariano-Goulart, D. see Sultan, A.

Marrero, D.G. see Carroll, A.E.

Marshall, S.M. see New, J.P.

Martínez-Godínez, M.A. see Navalón-García, K.

Martin, M.L. see Scanlon, P.H.

Martin, R.J.L., Savage, D.A., Carson, D.J., Maxwell, A.P. & Patterson, C.C. The PAX4 gene variant A1168C is not associated with early onset Type 1 diabetes in a UK population, 927

Martin, R.M. see Shultis, W.A.

Martin, S. see Hanifi-Moghaddam, P.

Martin, X. see Petruzzo, P.

Masding, M.G. see Coppini, D.V.



Masding, M.G., Stears, A.J., Burdge, G.C., Wootton, S.A. & Sandeman, D.D. The benefits of oestrogens on postprandial lipid metabolism are lost in post-menopausal women with Type 2 diabetes, 768

Mathiesen, E.R. see Nielsen, L.R.

Matsuhisa, M. see Nakatani, Y.

Matsumoto, K. see Miyamura, N.

Matsumura, T. see Miyamura, N.

Matsuoka, T. see Nakatani, Y.

Matteoli, M.C. see Pitocco, D.

Matthews, D.R. see Toh, V.

Matyka, K. Clinical Obesity in Adults and Children, 1160

Maxwell, A.P. see Martin, R.J.L.

Mazzanti, L. see Ferretti, G.

McAulay, V., Deary, I.J., Sommerfield, A.J. & Frier, B.M.
Attentional functioning is impaired during acute hypoglycaemia in people with Type 1 diabetes, 26

McCarthy, M.I. see Castleden, H.A.J.

McDonnell, C.M. see Ismail, D.

McElduff, A., Hitchman, R. & McElduff, P. Is sex hormone-binding globulin associated with glucose tolerance?, 306

McElduff, P. see McElduff, A.

McEwan, P. see Morgan, C.Ll.

McGee, D. see Lyons, T.J.

McGeough, E. see Geddes, J.

McHenry, M.B. see Lyons, T.J.

McKinney, P.A. see Feltbower, R.G.

McKnight, J.A. see Nyirenda, M.J.

McLean, M., Chipps, D. & Cheung, N.W. Mother to child transmission of diabetes mellitus: does gestational diabetes program Type 2 diabetes in the next generation?, 1213

McLoughney, C.R. see Khan, A.S.A.

Meeking, D.R. see Browne, D.L.

Meeking, D.R. see Wotherspoon, F.

Mencacci, M. see Celi, F.

Mendoza-Alcantar, L. see Navalón-García, K.

Meneveau, N. see Schiele, F.

Mercier, M. see Schiele, F.

Merrick, D. see Forouhi, N.

Merrick, D. see Forouhi, N.G.

Meyer, R. see Kessler, L.

Middleton, R.J. see New, J.P.

Miliar-García, A. see Navalón-García, K.

Millward, B.A. see Daly, M.E.

Millward, B.A. see Janghorbani, M.

Millward, B.A. see Stenhouse, E.

Milton, B., Holland, P. & Whitehead, M. The social and economic consequences of childhood-onset Type 1 diabetes mellitus across the lifecourse: a systematic review, 821

Minton, J.A.L. see Edghill, E.L.

Mirakian, R. see Moyes, V.

Misra, A. see Vikram, N.K.

Mitchie, D. see Arun, C.S.

Mithal, A. see Vikram, N.K.

Miwa, K. see Watarai, A.

Miyajima, H. see Muroi, R.

Miyake, I. see Hiromatsu, Y.

Miyamura, N., Murata, Y., Taketa, K., Ichihara, Y., Matsumura, T., Tokunaga, H., Matsumoto, K., Sakakida, M. & Araki, E. A case of insulin autoimmune syndrome with HLA DRB1*0404:

impact on the hypothesis for the molecular pathogenesis involving DRB1 molecules, 104

Mohamedi, H.M. see Mojiminiyi, O.A.

Mohan, V. see Adaikalakoteswari, A.

Mohan, V. see Rema, M.

Mohan, V., Gokulakrishnan, K., Sandeep, S., Srivastava, B.K., Ravikumar, R. & Deepa, R. Intimal media thickness, glucose intolerance and metabolic syndrome in Asian Indians—the Chennai Urban Rural Epidemiology Study (CURES –22), 845

Mojiminiyi, O.A., Abdella, N.A., Zaki, M.Y., El Gebely, S.A., Mohamedi, H.M. & Aldhahi, W.A. Prevalence and associations of low plasma erythropoietin in patients with Type 2 diabetes mellitus. 839

Mojtahedi, Z., Naeimi, S., Farjadian, S., Omrani, G.R. & Ghaderi, A. Association of IL-18 promoter polymorphisms with predisposition to Type 1 diabetes, 235

Molon, G., Targher, G., Costa, A., Bertolini, L., Barbieri, E. & Zenari, L. Measurement of microvolt T-wave alternans, a new arrhythmic risk stratification test, in Type 2 diabetic patients without clinical cardiovascular disease, 207

Moltz, K. see Laffel, L.M.B.

Montanaro, M. see Trento, M.

Morgan, C.Ll., McEwan, P., Morrissey, M., Peters, J.R., Poole, C. & Currie, C.J. Characterization and comparison of health-related utility in people with diabetes with various single and multiple vascular complications, 1100

Mori, M. see Shimizu, H.

Moroni, C. see Ferretti, G.

Morris, A.D. see Donnelly, L.A.

Morris, A.D. see Leese, G.P.

Morris, K. see Anderson, R.A.

Morrissey, M. see Morgan, C.L..

Mortensen, U.M., Nielsen-Kudsk, J.E., Sondergaard, H.M., Jakobsen, P., Jensen, B.S., Schmitz, O. & Nielsen, T.T. Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP-sensitive potassium channels, on walking distance in patients with intermittent claudication, 327

Moyes, V., Driver, R., Croom, A., Mirakian, R. & Chowdhury, T.A. Insulin allergy in a patient with Type 2 diabetes successfully treated with continuous subcutaneous insulin infusion, 204

Mukai, T. see Hiromatsu, Y.

Mukhopadhyay, B., Forouhi, N.G., Fisher, B.M., Kesson, C.M. & Sattar, N. A comparison of glycaemic and metabolic control over time among South Asian and European patients with Type 2 diabetes: results from follow-up in a routine diabetes clinic, 94

Mulder, J. see van de Laar, F.A.

Mulnier, H.E., Seaman, H.E., Raleigh, V.S., Soedamah-Muthu, S.S., Colhoun, H.M. & Lawrenson, R.A. Mortality in people with Type 2 diabetes in the UK, 516

Munday, J.L. see Browne, D.L.

Munday, L.J. see Wotherspoon, F.

Murata, Y. see Miyamura, N.

Muroi, R., Yagyu, H., Kobayashi, H., Nagata, M., Sato, N., Ideno, J., Fujita, N., Ando, A., Okada, K., Takiyama, Y., Nagasaka, S., Miyajima, H., Nakano, I. & Ishibashi, S. Early onset insulindependent diabetes mellitus as an initial manifestation of aceruloplasminaemia, 1136

Murphy, H.R., Rayman, G. & Skinner, T.C. Psycho-educational interventions for children and young people with Type 1 diabetes, 935 Musacchio, E. see Marfella, R. Mustafa, N. see Peter, R.

Mustapic, D. see Maier, C.

Nóvoa, F.J. see Boronat, M.

Naeimi, S. see Mojtahedi, Z. Nagasaka, S. see Muroi, R.

Nagata, M. see Muroi, R.

Nakae, M. see Watarai, A.

Nakamura, J. see Watarai, A.

Nakano, I. see Muroi, R.

Nakashima, E. see Watarai, A.

Nakatani, Y., Kaneto, H., Hatazaki, M., Yoshiuchi, K., Kawamori, D., Sakamoto, K., Matsuoka, T., Ogawa, S., Yamasaki, Y. & Matsuhisa, M. Increased stress protein ORP150 autoantibody production in Type 1 diabetic patients, 216

Nakayama, H. see Hiromatsu, Y.

Namba, M. see Satani, K.

Nanetti, L. see Ferretti, G.

Naruse, K. see Watarai, A.

Navalón-García, K., Mendoza-Alcantar, L., Díaz-Vargas, M.E., Martínez-Godínez, M.A., Reyna-Garfias, H., Aguilar-Salinas, C.A., Riba, L., Canizales-Quinteros, S., Villarreal-Molina, T., González-Chávez, A., Argueta-Villamar, V., Tusié-Luna, M.T. & Miliar-García, A. HNF-1α G574S is a functional variant with decreased transactivation activity, 1295

Nazir, F.S., Alem, M., Small, M., Connell, J.M.C., Lees, K.R., Walters, M.R. & Cleland, S.J. Blunted response to systemic nitric oxide synthase inhibition in the cerebral circulation of patients with Type 2 diabetes, 398

Nelson, E.A. see O'Meara, S.

Nelson, E.A., O'Meara, S., Golder, S., Dalton, J., Craig, D. & Iglesias, C., on behalf of the DASIDU Steering Group.

Systematic review of antimicrobial treatments for diabetic foot ulcers. 348

Nelson, R.G. see Wolford, I.K.

Ness, A.R. see Shultis, W.A.

New, J.P., O'Donoghue, D.J., Middleton, R.J., Rudenski, A., Dasgupta, I., Bilous, R.W. & Marshall, S.M. Time to move from serum creatinine to eGFR, 1047

Nicoletti, G.F. see Marfella, R.

Nielsen, L.R., Müller, C., Damm, P. & Mathiesen, E.R. Reduced prevalence of early preterm delivery in women with Type 1 diabetes and microalbuminuria—possible effect of early antihypertensive treatment during pregnancy, 426

Nielsen, T.T. see Mortensen, U.M.

Nielsen-Kudsk, J.E. see Mortensen, U.M.

Niessen, L.W. see Dijkstra, R.F.

Niwa, T. see Watarai, A.

Nomura, A. see Tsutsumi, Y.

Noordam, C. see Edghill, E.L.

Norris, S.L., Chowdhury, F.M., Van Le, K., Horsley, T., Brownstein, J.N., Zhang, X., Jack Jr, L. & Satterfield, D.W. Effectiveness of community health workers in the care of persons with diabetes, 544

Northam, E.A., Todd, S. & Cameron, F.J. Interventions to promote optimal health outcomes in children with Type 1 diabetes—are they effective?, 113

Nugara, F. see Godsland, I.F.

Nyirenda, M.J., Sandeep, T., Grant, I., Price, G. & McKnight, J.A. Severe acidosis in patients taking metformin—rapid reversal and survival despite high APACHE score, 432

Östenson, C.-G. see Yngen, M.

O'Dea, K. see Hodge, A.M.

O'Donoghue, D.J. see New, J.P.

O'Meara, S. see Nelson, E.A.

O'Meara, S., Nelson, E.A., Golder, S., Dalton, J.E., Craig, D. & Iglesias, C., on behalf of the DASIDU Steering Group. Systematic review of methods to diagnose infection in foot ulcers in diabetes, 341

O'Connor, M.E. see Raji, A.

O'Neill, M.C. see Viberti, G.

Odén, A. see Brohall, G.

Oda, E. Cut points of waist circumference for Japanese people, 1385

Ogawa, S. see Nakatani, Y.

Oh, B. see Park, K.S.

Oh, B. see Shin, H.D.

Oh-I, S. see Shimizu, H.

Ohtani, K.-I. see Shimizu, H.

Oiso, Y. see Watarai, A.

Okada, K. see Muroi, R.

Okada, S. see Shimizu, H.

Olivarius, N. de F. see Heldgaard, P.E.

Omrani, G.R. see Mojtahedi, Z.

Ong, C.N. see Lim, S.C.

Optenhostert-Porst, C. see Lobnig, B.M.

Ortega, F. see Kessler, L.

Otvos, J.D. see Lyons, T.J.

Owen, C. see Whincup, P.

Owen, N. see Xu, F.

Owens, D.R. see Peter, R.

Ozmen, S., Cil, T., Atay, A.E., Tuzcu, A.K. & Bahceci, M. A simple way to estimate mean plasma glucose and to identify Type 2 diabetic subjects with poor glycaemic control when a standardized HbA_{1c} assay is not available, 1151

Padovani, R. see Targher, G.

Pagliari, C. see Franklin, V.L.

Paisey, R. see Daly, M.E.

Palin, S.L. & Gough, S.C. Rupture of the Achilles tendon associated with ciprofloxacin, 1386

Pallisco, O. see Fornengo, P.

Palmer, A.J. see Roze, S.

Pampanelli, S. see Perriello, G.

Pandey, R.M. see Vikram, N.K.

Papadopoulos, C.E. see Karamitsos, T.D.

Papi, F. see Celi, F.

Parharidis, G.E. see Karamitsos, T.D.

Park, B.L. see Park, K.S.

Park, B.L. see Shin, H.D.

Park, C. see Cho, N.H.

Park, C. see Shin, H.D.

Park, C.-S. see Park, K.S.

Park, J.H., Kim, W.H., Kim, J.H., Park, T.S. & Baek, H.S.Prevalence of and risk factors for extracranial internal carotid

artery stenosis in Korean Type 2 diabetic patients, 1377 Park, J.Y. see Cho, N.H.

Park, K.S. see Shin, H.D.

Park, K.S., Shin, H.D., Park, B.L., Cheong, H.S., Cho, Y.M., Lee, H.K., Lee, J.-Y., Lee, J.-K., Kim, H.T., Park, C.-S., Han, B.G., Kimm, K. & Oh, B. Putative association of peroxisome proliferator-activated receptor γ co-activator 1β (*PPARGC1B*) polymorphism with Type 2 diabetes mellitus, 635

Park, T.S. see Cho, N.H.

Park, T.S. see Park, J.H.

Parkkonen, M. see Bahr, C.

Parkkonen, M. see Turunen, J.A.

Parving, H.-H. see Lajer, M.

Pascale, C. see Fornengo, P.

Patera, I.P. see Pitocco, D.

Patterson, C.C. see Martin, R.J.L.

Pauvaday, V. see Peter, R.

Pavlic-Renar, I. see Kølendorf, K.

Pearson, E.R. see Castleden, H.A.J.

Pearson, E.R. see Donnelly, L.A.

Pecher, E. see Ristic, S.

Pedersen, O. see Wegner, L.

Pedersen-Bjergaard, U. see Akram, K.

Pegge, N.C., Twomey, A.M., Vaughton, K., Gravenor, M.B., Ramsey, M.W. & Price, D.E. The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment, 873

Peltonen, M. see Borodulin, K.

Penfornis, A. see Schiele, F.

Peng, J. see Zhang, D.

Perriello, G. see Kølendorf, K.

Perriello, G., Pampanelli, S., Di Pietro, C. & Brunetti, P., on behalf of the Italian Pioglitazone Study Group. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes, 246

Peter, R., Luzio, S.D., Dunseath, G., Pauvaday, V., Mustafa, N. & Owens, D.R. Relationship between HbA_{1c} and indices of glucose tolerance derived from a standardized meal test in newly diagnosed treatment naive subjects with Type 2 diabetes, 990

Peters, J.L. see Ali, S.

Peters, J.R. see Morgan, C.Ll.

Petersen, K.-G. see Slawik, M.

Petrelli, A. see Giorda, C.

Petrie, J. see Leese, G.P.

Petruzzo, P., Badet, L., Lefrançois, N., Berthillot, C., Dorel, S.B., Martin, X. & Laville, M. Metabolic consequences of pancreatic systemic or portal venous drainage in simultaneous pancreaskidney transplant recipients, 654

Peveler, R. see Barnard, K.D.

Pfützner, A. see Pfützner, J.

Pfützner, A.H. see Pfützner, J.

Pfützner, J., Forst, T., Butzer, R., Forst, S., Weber, M.M.,
Pfützner, A.H. & Pfützner, A. Performance of the continuous
glucose monitoring system (CGMS) during development of
ketosis in patients on insulin pump therapy, 1124

Pfohl, M. see Hoogma, R.P.L.M.

Phenekos, C. see Stewart, M.W.

Phillips, L.S. see Rhee, M.K.

Philotheou, A. see Kølendorf, K.

Phiri, R., Keeffe, J.E., Harper, C.A. & Taylor, H.R. Comparative study of the polaroid and digital non-mydriatic cameras in the detection of referrable diabetic retinopathy in Australia, 867

Pieber, T.R. see Schaller, H.C.

Piemont, Y. see Kessler, L.

Pietryga, M. see Dworacka, M.

Pinget, M. see Kessler, L.

Piot, C. see Sultan, A.

Pitocco, D., Crinò, A., Di Stasio, E., Manfrini, S., Guglielmi, C., Spera, S., Anguissola, G.B., Visalli, N., Suraci, C., Matteoli, M.C., Patera, I.P., Cavallo, M.G., Bizzarri, C. & Pozzilli, P., on behalf of the IMDIAB Group. The effects of calcitriol and nicotinamide on residual pancreatic β-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI), 920

Plummer, C.J. What's in the CARDS?, 711

Plunkett, M. see Porter, J.R.

Poli, F. see Targher, G.

Pomerantz, K. see Cho, N.H.

Poole, C. see Morgan, C.Ll.

Porta, M. see Trento, M.

Porter, J.R., Rangasami, J.J., Ellard, S., Gloyn, A.L., Shields, B.M., Edwards, J., Anderson, J.M., Shaw, N.J., Hattersley, A.T., Frayling, T.M., Plunkett, M. & Barrett, T.G. Asian MODY: are we missing an important diagnosis?, 1257

Pozzilli, P. see Pitocco, D.

Prázny, M. see Ma, J.

Pradhan, A.D., Manson, J.E., Hendrix, S.L., Johnson, K.C., Wagenknecht, L.E., Haan, M.N., Weidner, G., LaCroix, A.Z. & Cook, N.R. Cross-sectional correlates of fasting hyperinsulinaemia in post-menopausal women of different ethnic origin, 77

Price, D.E. see Pegge, N.C.

Price, G. see Nyirenda, M.J.

Pulkkinen, L. see Mager, U.

Punnose, J. see Agarwal, M.M.

Qu, Y.C. see Sun, L.

Rabini, R.A. see Ferretti, G.

Raccah, D. see Sejil, S.

Raji, A., Gerhard-Herman, M.D., Williams, J.S., O'Connor, M.E. & Simonson, D.C. Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians, 537

Raleigh, V.S. see Mulnier, H.E.

Rambod, M. see Hosseinpanah, F.

Ramos, E. see Hazard, I.

Ramsey, M.W. see Pegge, N.C.

Rangasami, J.J. see Porter, J.R.

Ravikumar, R. see Mohan, V.

Rayman, G. see Murphy, H.R.

Redaelli, M. see Stock, S.A.K.

Rees, A. see Anderson, R.A.

Reincke, M. see Slawik, M.

Reintjes, R. see von Sengbusch, S.

Rema, M. see Adaikalakoteswari, A.

Rema, M., Srivastava, B.K., Anitha, B., Deepa, R. & Mohan, V. Association of serum lipids with diabetic retinopathy in urban South Indians—the Chennai Urban Rural Epidemiology Study (CURES) Eye Study—2, 1029

Renard, E. see Sultan, A.

Rendas-Baum, R. see Roy, M.

Resnick, H.E. see Davidson, M.

Reyna-Garfias, H. see Navalón-García, K.

Reza Ghaffari, H.R. see Hosseinpanah, F.

Rhee, M.K., Ziemer, D.C., Kolm, P. & Phillips, L.S. Postchallenge glucose rises with increasing age even when glucose tolerance is normal, 1174

Rhodes, P. see Ismail, H.

Riba, L. see Navalón-García, K.

Richardson, C. see Wise, S.

Richardson, T. see Kerr, D.

Richmond, W. see Godsland, I.F.

Ristic, S., Collober-Maugeais, C., Pecher, E. & Cressier, F. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone, 757

Roach, P. & Malone, J.K. Comparison of insulin lispro mixture 25/ 75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes, 743

Robbins, D.C. see Davidson, M.

Robertson, N., Burden, M.L. & Burden, A.C. Psychological morbidity and problems of daily living in people with visual loss and diabetes: do they differ from people without diabetes?,

Roep, B.O. see Hanifi-Moghaddam, P.

Rooney, D.P. & Ryan, M.F. Diabetes with partial lipodystrophy following sclerodermatous chronic graft vs. host disease, 436

Rosenfalck, A.M., Almdal, T., Viggers, L., Madsbad, S. & Hilsted, J. A low-fat diet improves peripheral insulin sensitivity in patients with Type 1 diabetes, 384

Ross, G.P. see Kølendorf, K.

Rowan, J.A. see Hughes, R.C.E.

Rowlands, D.S. see Johnson, N.A.

Roy, M., Rendas-Baum, R. & Skurnick, J. Mortality in African-Americans with Type 1 diabetes: The New Jersey 725, 698

Roze, S., Valentine, W.J., Zakrzewska, K. & Palmer, A.J. Response to the letter by Philip Home, 707

Rubens, M.B. see Godsland, I.F.

Rudenski, A. see New, J.P.

Ruggiero, L. see Marfella, R.

Ruotolo, G. see Davidson, M.

Rutten, G.E.H.M. see van de Laar, F.A.

Ryan, M.F. see Rooney, D.P.

Sørensen, H.T. see Kruse, A.

Saavedra, P. see Boronat, M.

Sachinwalla, T. see Johnson, N.A.

Sakakida, M. see Miyamura, N.

Sakamoto, K. see Nakatani, Y.

Salman, S. see Ertugrul, M.B.

Samaranayake, L.P. see Soysa, N.S.

Sampson, M. see Castleden, H.A.J.

Sampson, M.J., Crowle, T., Dhatariya, K., Dozio, N., Greenwood, R.H., Heyburn, P.J., Jones, C., Temple, R.C. & Walden, E. Trends in bed occupancy for inpatients with diabetes before and after the introduction of a diabetes inpatient specialist nurse service, 1008

Sandbaek, A. Reply, 1042

Sandeep, S. see Mohan, V.

Sandeep, T. see Nyirenda, M.J.

Sandeman, D.D. see Masding, M.G.

Sanderman, R. see Hagedoorn, M.

Santilli, E. see Celi, F.

Saris, W.H.M. see Corpeleijn, E.

Saron, C. see Marfella, R.

Sasso, F.C. see Marfella, R.

Satani, K., Konya, H., Hamaguchi, T., Umehara, A., Katsuno, T., Ishikawa, T., Kohri, K., Hasegawa, Y., Suehiro, A., Kakishita, E. & Namba, M. Clinical significance of circulating hepatocyte growth factor, a new risk marker of carotid atherosclerosis in patients with Type 2 diabetes, 617

Sato, N. see Muroi, R.

Sattar, N. see Mukhopadhyay, B.

Satterfield, D.W. see Norris, S.L.

Savage, D.A. see Martin, R.J.L.

Scala, L. see Targher, G.

Scally, A. see Ismail, H.

Scanlon, P.H., Martin, M.L., Bailey, C., Johnson, E., Hykin, P. & Keightley, S. Reported symptoms and quality-of-life impacts in patients having laser treatment for sight-threatening diabetic retinopathy, 60

Schønheyder, H.C. see Kruse, A.

Schön, S. see Bahr, C.

Schaller, H.C., Schaupp, L., Bodenlenz, M., Wilinska, M.E., Chassin, L.J., Wach, P., Vering, T., Hovorka, R. & Pieber, T.R. On-line adaptive algorithm with glucose prediction capacity for subcutaneous closed loop control of glucose: evaluation under fasting conditions in patients with Type 1 diabetes, 90

Schaupp, L. see Schaller, H.C.

Schiele, F., Descotes-Genon, V., Seronde, M.F., Blonde, M.C., Legalery, P., Meneveau, N., Ecarnot, F., Mercier, M., Penfornis, A., Thebault, L., Boumal, D. & Bassand, J-P., on behalf of the investigators of the 'Réseau Franc Comtois de Cardiologie'. Predictive value of admission hyperglycaemia on mortality in patients with acute myocardial infarction, 1370

Schjoedt, K.J. see Lajer, M.

Schloot, N.C. see Hanifi-Moghaddam, P.

Schmitz, O. see Mortensen, U.M.

Schories, M. see Slawik, M.

Schuster, E. see Maier, C.

Schweitzer, D.H. see Hoogma, R.P.L.M.

Scoccianti, L. see Trento, M.

Scott, J. see Shultis, W.A.

Scottish Study Group for the Care of the Young with Diabetes. A longitudinal observational study of insulin therapy and glycaemic control in Scottish children with Type 1 diabetes: DIABAUD 3, 1216

Seaman, H.E. see Mulnier, H.E.

Seissler, J. see Hanifi-Moghaddam, P.

Sejil, S., Janand-Delenne, B., Avierinos, J.-F., Habib, G., Labastie, N., Raccah, D., Vague, P. & Lassmann-Vague, V. Six-year follow-up of a cohort of 203 patients with diabetes after screening for silent myocardial ischaemia, 1186

Sekido, Y. see Watarai, A.

Seronde, M.F. see Schiele, F.

Shaban, M.C., Fosbury, J., Kerr, D. & Cavan, D.A. The prevalence of depression and anxiety in adults with Type 1 diabetes, 1381

Shah, B.R., Hux, J.E., Laupacis, A., Zinman, B. & Booth, G.L. Use of vascular risk-modifying medications for diabetic patients differs between physician specialties, 1117

Shakespeare, L. see Agius, E.

Sharma, S. see Vikram, N.K.

Shashaj, B. see Sulli, N.

Shaw, J. see Alberti, K.G.M.M.

Shaw, K.M. see Browne, D.L.

Shaw, K.M. see Wotherspoon, F.

Shaw, N.J. see Porter, J.R.

Shi, X.H. see Sun, L.

Shields, B. see Castleden, H.A.J.

Shields, B.M. see Porter, J.R.

Shimizu, H., Oh-I, S., Tsuchiya, T., Ohtani, K.-I., Okada, S. & Mori, M. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-α levels in Type 2 diabetic patients: a randomized study, 253

Shin, H.D. see Park, K.S.

Shin, H.D., Park, K.S., Park, B.L., Cheong, H.S., Cho, Y.M., Lee, H.K., Lee, J.-Y., Lee, J.-K., Kim, H.T., Han, B.G., Kim, J.W., Koh, I., Kim, Y.J., Oh, B., Kimm, K. & Park, C. Common promoter polymorphism in monocyte differentiation antigen CD14 is associated with serum triglyceride levels and body mass index in non-diabetic individuals, 72

Shoji, S. see Hiromatsu, Y.

Shotliff, K.P. & Duncan, G. Diabetic retinopathy screening programmes and reducing ophthalmologists' workload, 449

Shotton, M. see Arun, C.S.

Shrestha, U.K., Singh, D.L. & Bhattarai, M.D. The prevalence of hypertension and diabetes defined by fasting and 2-h plasma glucose criteria in urban Nepal, 1130

Shultis, W.A., Leary, S.D., Ness, A.R., Scott, J., Martin, R.M., Whincup, P.H. & Smith, G.D., the ALSPAC Study Team. Haemoglobin A_{1c} is not a surrogate for glucose and insulin measures for investigating the early life and childhood determinants of insulin resistance and Type 2 diabetes in healthy children. An analysis from the Avon Longitudinal Study of Parents and Children (ALSPAC), 1357

Shutler, S.D. see Ashwell, S.G.

Sidelmann, J.J. see Heldgaard, P.E.

Simmons, D. see Cutchie, W.A.

Simmons, D. see Kerr, G.D.

Simon, D. see Cogneau, J.

Simonson, D.C. see Raji, A.

Singh, B.M. see Baskar, V.

Singh, D.L. see Shrestha, U.K.

Siniscalchi, M. see Marfella, R.

Skinner, T.C. see Barnard, K.D.

Skinner, T.C. see Murphy, H.R.

Skinner, T.C. What does make the difference?, 933

Skrivanek, Z. see Linnebjerg, H.

Skurnick, J. see Roy, M.

Slawik, M., Schories, M., Busse Grawitz, A., Reincke, M. & Petersen, K.-G. Treatment with insulin glargine does not suppress serum IGF-1, 814

Slingerland, A.S. see Edghill, E.L.

Small, M. see Nazir, F.S.

Smith, G D. see Shultis, W.A.

Snoek, F.J. see van Esch, S.C.M.

Soedamah-Muthu, S.S. see Mulnier, H.E.

Somda, F. see Tauveron, I.

Sommerfield, A.J. see McAulay, V.

Sondergaard, H.M. see Mortensen, U.M.

Song, Y., He, K., Levitan, E.B., Manson, J.E. & Liu, S. Effects of oral magnesium supplementation on glycaemic control in Type 2

diabetes: a meta-analysis of randomized double-blind controlled trials, 1050

Soysa, N.S., Samaranayake, L.P. & Ellepola, A.N.B. Diabetes mellitus as a contributory factor in oral candidosis, 455

Sparsø, T. see Wegner, L.

Spera, S. see Pitocco, D.

Spruce, M.C. see Coppini, D.V.

Srivastava, B.K. see Mohan, V.

Srivastava, B.K. see Rema, M.

Srivastava, M.C. see Vikram, N.K.

Stafleu, A. see van de Laar, F.A.

Stannard, K.P. see Arun, C.S.

Stannard, S.R. see Johnson, N.A.

Starkie, M.G. see Stewart, M.W.

Stears, A.J. see Masding, M.G.

Stenhouse, E., Wright, D.E., Hattersley, A.T. & Millward, B.A. Maternal glucose levels influence birthweight and 'catch-up' and 'catch-down' growth in a large contemporary cohort, 1207

Stenhouse, E.A. see Janghorbani, M.

Stenström, G. see Berger, B.

Stephens, J.W. & Williams, R. Time to stop talking about screening for diabetes?, 1163

Stephens, J.W. see Ashwell, S.G.

Stephenson, C.R. see Feltbower, R.G.

Stewart, J.A. see Gerstein, H.C.

Stewart, M.W., Cirkel, D.T., Furuseth, K., Donaldson, J., Biswas, N., Starkie, M.G., Phenekos, C. & Hamann, A. Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes, 1069

Stock, S.A.K., Redaelli, M., Wendland, G., Civello, D. & Lauterbach, K.W. Diabetes—prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany, 299

Stone, M.A. see Ali, S.

Strassburger, K. see Hanifi-Moghaddam, P.

Suárez, V. see Boronat, M.

Su, D.-H., Lai, M.-Y. & Wu, H.-P. Liver failure in a patient receiving rosiglitazone therapy, 105

Subramaniam, T. see Lim, S.C.

Suehiro, A. see Satani, K.

Sulli, N. & Shashaj, B. Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up, 900

Sultan, A., Piot, C., Mariano-Goulart, D., Daures, J.P., Comte, F., Renard, E. & Avignon, A. Myocardial perfusion imaging and cardiac events in a cohort of asymptomatic patients with diabetes living in southern France, 410

Sum, C.F. see Lim, S.C.

Sun, G.Z. see Yang, J.K.

Sun, L., Yang, Z., Jin, F., Zhu, X.Q., Qu, Y.C., Shi, X.H. & Wang, L. The Gly482Ser variant of the PPARGC1 gene is associated with Type 2 diabetes mellitus in northern Chinese, especially men, 1085

Sun, T.B., Yang, C.C.H. & Kuo, T.B.J. Effect of hyperbaric oxygen on cardiac neural regulation in diabetic individuals with foot complications, 360

Sundkvist, G. see Berger, B.

Sundquist, K. & Li, X. Type 1 diabetes as a risk factor for stroke in men and women aged 15–49: a nationwide study from Sweden, 1261 Sundvall, J. see Borodulin, K.

Suraci, C. see Pitocco, D.

Sutherland, M.G. see Gill, E.A.

Sutton, S. see Farmer, A.

Szczawinska, K. see Dworacka, M.

Takada, H. see Tsutsumi, Y.

Takata, K. see Hiromatsu, Y.

Taketa, K. see Miyamura, N.

Takiyama, Y. see Muroi, R.

Tan, H.H. see Lim, S.C.

Tan, I.K. see Lim, S.C.

Tandon, N. see Vikram, N.K.

Targher, G. see Molon, G.

Targher, G., Bertolini, L., Padovani, R., Poli, F., Scala, L., Tessari, R., Zenari, L. & Falezza, G. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with nonalcoholic fatty liver disease, 403

Targher, G., Bertolini, L., Tessari, R., Zenari, L. & Arcaro, G. The International Diabetes Federation definition of the metabolic syndrome independently predicts future cardiovascular events in Type 2 diabetic patients. The Valpolicella Heart Diabetes Study, 1270

Targher, G. Obesity and Diabetes, 1388

Tarnow, L. see Lajer, M.

Tauveron, I., Delcourt, I., Desbiez, F., Somda, F. & Thiéblot, P. Canine detection of hypoglycaemic episodes whilst driving,

Taylor, H.R. see Phiri, R.

Taylor, R. see Arun, C.S.

Tee, W.W. see Lim, S.C.

Temple, R.C. see Sampson, M.J.

Ter Maaten, J.C. see Hagedoorn, M.

Tessari, R. see Targher, G.

The DIAMOND Project Group. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999, 857

The ESRD Incidence Study Group. Divergent trends in the incidence of end-stage renal disease due to Type 1 and Type 2 diabetes in Europe, Canada and Australia during 1998-2002, 1364

Thebault, L. see Schiele, F.

Thiéblot, P. see Tauveron, I.

Thomas, M.C., Tsalamandris, C., MacIsaac, R. & Jerums, G. Functional erythropoietin deficiency in patients with Type 2 diabetes and anaemia, 502

Thomas, P. see Coppini, D.V.

Thompson, C.H. see Johnson, N.A.

Thompson, M.W. see Johnson, N.A.

Thomsen, R.W. see Kruse, A.

Thorsteinsson, B. see Akram, K.

Todd, S. see Northam, E.A.

Toh, V., Duncan, E., Lewis, N., Fichter, L. & Matthews, D.R. Ergotamine use in severe diabetic autonomic neuropathy, 574

Tokunaga, H. see Miyamura, N.

Tolis, G. see Angelopoulos, N.G.

Tomelini, M. see Trento, M.

Torlone, E. see Hoogma, R.P.L.M.

Toth, E.L. see Johnson, J.A.

Tovar, A. see Laffel, L.M.B.

Tracy, R.P. see Davidson, M.

Trautmann, M.E. see Linnebjerg, H.

Trento, M., Tomelini, M., Lattanzio, R., Brancato, R., Coggiola, A., Benecchi, R., Scoccianti, L., Insacco, C., Bandello, F., Montanaro, M., Cavallo, F. & Porta, M. Perception of, and anxiety levels induced by, laser treatment in patients with sight-threatening diabetic retinopathy. A multicentre study, 1106

Tsalamandris, C. see Thomas, M.C.

Tsuchiya, T. see Shimizu, H.

Tsutsumi, Y., Jie, X., Ihara, K., Nomura, A., Kanemitsu, S., Takada, H. & Hara, T. Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with Type 1 diabetes, 1145

Tuomilehto, J. see Borodulin, K.

Tuomilehto, J. see Mager, U.

Turner, C. see Wotherspoon, F.

Turunen, J.A., Wessman, M., Kilpikari, R., Parkkonen, M., Forsblom, C. & Groop, P-H., on behalf of the FinnDiane Study Group. The functional variant -169C/T in the FCRL3 gene does not increase susceptibility to Type 1 diabetes, 925

Tusek, C. see Bott, S.

Tusié-Luna, M.T. see Navalón-García, K.

Tuzcu, A.K. see Ozmen, S.

Twomey, A.M. see Pegge, N.C.

Umehara, A. see Satani, K.

Unal, S. see Ertugrul, M.B.

Uusitupa, M. see Mager, U.

Vague, P. see Sejil, S.

Vaidya, B. see Castleden, H.A.J.

Valentine, W.J. see Roze, S.

Valle, T.T. see Mager, U.

van de Laar, F.A., van de Lisdonk, E.H., Lucassen, P.L.B.J., Stafleu, A., Mulder, J., van den Hoogen, H.J.M., Rutten, G.E.H.M. & van Weel, C. Eating behaviour and adherence to diet in patients with Type 2 diabetes mellitus, 788

van de Lisdonk, E.H. see van de Laar, F.A.

van den Hoogen, H.J.M. see van de Laar, F.A.

van der Kallen, C.J.H. see Corpeleijn, E.

van Esch, S.C.M., Cornel, M.C. & Snoek, F.J. Type 2 diabetes and inheritance: what information do diabetes organizations provide on the Internet?, 1233

Van Le, K. see Norris, S.L.

van Weel, C. see van de Laar, F.A.

Varillas, V.F. see Boronat, M.

Vaughton, K. see Pegge, N.C.

Venugopal, H. see Baskar, V. Vering, T. see Schaller, H.C.

Verza, M. see Marfella, R.

Viberti, G., Lachin, J., Holman, R., Zinman, B., Haffner, S., Kravitz, B., Heise, M.A., Jones, N.P., O'Neill, M.C., Freed, M.I., Kahn, S.E. & Herman, W.H. for the ADOPT Study Group. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe, 1289

Vidya, M.-A. see Agius, E.

Viggers, L. see Rosenfalck, A.M.

Vignini, A. see Ferretti, G.

Vikram, N.K., Tandon, N., Misra, A., Srivastava, M.C., Pandey, R.M., Mithal, A., Sharma, S., Ajmani, A., Madhu, S.V., Batra, C.M. & Gupta, N. Correlates of Type 2 diabetes mellitus in



children, adolescents and young adults in north India: a multisite collaborative case-control study, 293

Villarreal-Molina, T. see Navalón-García, K.

Visalli, N. see Pitocco, D.

von Sengbusch, S., Müller-Godeffroy, E., Häger, S., Reintjes, R., Hiort, O. & Wagner, V. Mobile diabetes education and care: intervention for children and young people with Type 1 diabetes in rural areas of northern Germany, 122

Vuillermin, P.J. see Ismail, D.

Wach, P. see Schaller, H.C.

Wagenknecht, L.E. see Bowden, D.W.

Wagenknecht, L.E. see Burdon, K.P.

Wagenknecht, L.E. see Pradhan, A.D.

Wagner, V. see von Sengbusch, S.

Walden, E. see Sampson, M.J.

Walker, B.R. Cortisol—cause and cure for metabolic syndrome?, 1281

Walker, M. see Castleden, H.A.J.

Wallén, N.H. see Yngen, M.

Waller, A. see Franklin, V.L.

Wallymahmed, M. see Woodward, A.

Walters, M.R. see Nazir, F.S.

Wang, C. see Hu, C.

Wang, H. see Liu, L.

Wang, L. see Sun, L.

Wang, L. see Yang, J.K.

Ware, R. see Xu, F.

Watanabe, G. see Watarai, A.

Watarai, A., Nakashima, E., Hamada, Y., Watanabe, G., Naruse, K., Miwa, K., Kobayashi, Y., Kamiya, H., Nakae, M., Hamajima, N., Sekido, Y., Niwa, T., Oiso, Y. & Nakamura, J. Aldose reductase gene is associated with diabetic macroangiopathy in Japanese Type 2 diabetic patients, 894

Webb, D. see Ferriss, J.B.

Weber, M.M. see Pfützner, J.

Wegner, L., Andersen, G., Albrechtsen, A., Sparsø, T., Glümer, C., Borch-Johnsen, K., Jørgensen, T., Hansen, T. & Pedersen, O. Large-scale study of the −232C > G polymorphism of *PCK1* in Type 2 diabetes, 1140

Weidner, G. see Pradhan, A.D.

Weill, A. see Cogneau, J.

Wender-Ożegowska, E. see Dworacka, M.

Wendland, G. see Stock, S.A.K.

Weng, J. see Zhang, D.

Wentzell, K. see Laffel, L.M.B.

Wessman, M. see Bahr, C.

Wessman, M. see Turunen, J.A.

Whincup, P., Gilg, J., Owen, C., Cook, D. & Alberti, K.G.M.M. Authors' reply, 336

Whincup, P.H. see Shultis, W.A.

White, K.E. Research into the glomerular podocyte—is it relevant to diabetic nephropathy?, 715

Whitehead, M. see Milton, B.

Wiefels, K.J. see Hoogma, R.P.L.M.

Wild, S. see Forouhi, N.

Wild, S.H. see Forouhi, N.G.

Wilding, J. see Woodward, A.

Wilinska, M.E. see Schaller, H.C.

Williams, A.J.K. see Castleden, H.A.J.

Williams, J.S. see Raji, A.

Williams, K. see Daly, M.E.

Williams, R. see Deakin, T.A.

Williams, R. see Stephens, J.W.

Wilson, A.W. see Franklin, V.L.

Winiarska, H. see Dworacka, M.

Wise, S., Chien, J., Yeo, K. & Richardson, C. Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly-Dura inhaled insulin system, 510

Wolf, O.T. see Lobnig, B.M.

Wolford, J.K., Yeatts, K.A., Eagle, A.R.R., Nelson, R.G., Knowler, W.C. & Hanson, R.L. Variants in the gene encoding aldose reductase (AKR1B1) and diabetic nephropathy in American Indians, 367

Woodward, A. see Daousi, C.

Woodward, A., Wallymahmed, M., Wilding, J. & Gill, G. Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm, 780

Wootton, S.A. see Masding, M.G.

Wotherspoon, F., Laight, D.W., Browne, D.L., Turner, C., Meeking, D.R., Allard, S.E., Munday, L.J., Shaw, K.M. & Cummings, M.H. Plasma homocysteine, oxidative stress and endothelial function in patients with Type 1 diabetes mellitus and microalbuminuria, 1350

Wright, D.E. see Stenhouse, E.

Wright, J. see Ismail, H.

Wu, B.Y. see Yang, J.K.

Wu, H.-P. see Su, D.-H.

Wu, Y.S. see Lim, S.C.

Xiang, K. see Hu, C.

Xiu, L. see Zhang, D.

Xu, F., Yin, X.M., Zhang, M., Leslie, E., Ware, R. & Owen, N. Family average income and diagnosed Type 2 diabetes in urban and rural residents in regional mainland China, 1239

Xu, X. see Yang, J.K.

Xu, X.H. see Lim, S.C.

Xu, X.P. see Yang, J.K.

Yagyu, H. see Muroi, R.

Yale, J.-F. see Gerstein, H.C.

Yamada, K. see Hiromatsu, Y.

Yamasaki, Y. see Nakatani, Y.

Yang, C.C.H. see Sun, T.B.

Yang, G.R. see Yang, J.K.

Yang, J.K., Feng, Y., Yuan, M.Y., Yuan, S.Y., Fu, H.J., Wu, B.Y., Sun, G.Z., Yang, G.R., Zhang, X.L., Wang, L., Xu, X., Xu, X.P. & Chan, J.C.N. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS, 623

Yang, Z. see Sun, L.

Yap, E. see Lim, S.C.

Yeatts, K.A. see Wolford, J.K.

Yeo, K. see Wise, S.

Yin, X.M. see Xu, F.

Yngen, M., Östenson, C.-G., Hjemdahl, P. & Wallén, N.H. Mealinduced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide, 134

Yoon, T.H. see Ahn, J.H.

Yoshiuchi, K. see Nakatani, Y.

Young, B. & Dean, J.D. Guest editorial, 1277 Young, D. see Arun, C.S. Yu, Q. see Liu, L. Yu, Y. see Lyons, T.J. Yuan, M.Y. see Yang, J.K. Yuan, S.Y. see Yang, J.K.

Zaki, M.Y. see Mojiminiyi, O.A. Zakrzewska, K. see Roze, S. Zawiejska, A. see Dworacka, M. Zenari, L. see Molon, G. Zenari, L. see Targher, G. Zervas, A. see Angelopoulos, N.G. Zhang, C. see Zhang, D. Zhang, D., Zhou, Z., Li, L., Weng, J., Huang, G., Jing, P., Zhang, C., Peng, J. & Xiu, L. Islet autoimmunity and genetic mutations in

Chinese subjects initially thought to have Type 1B diabetes, 67

Zhang, H.-L. see Jian, W.-X. Zhang, M. see Hughes, R.C.E. Zhang, M. see Xu, F. Zhang, R. see Hu, C. Zhang, S.X. see Liu, L. Zhang, X. see Norris, S.L. Zhang, X.L. see Yang, J.K. Zhao, Y. see Jian, W.-X. Zheng, D. see Lyons, T.J. Zheng, S. see Jian, W.-X. Zhou, Z. see Zhang, D. Zhu, J. see Davidson, M. Zhu, X.Q. see Sun, L. Ziemer, D.C. see Rhee, M.K. Zimmet, P. see Alberti, K.G.M.M. Zinman, B. see Shah, B.R. Zinman, B. see Viberti, G.



Subject Index

–232C/ G polymorphism, 419 1, 171 11β-hydroxysteroid dehydrogenase, 1281 5-anhydro-D-glucitol, 171

α-glucosidase inhibitor, 253 abdominal obesity, 1025 accumulation, 522 aceruloplasminaemia, 1136 acute hyperglycaemia, 171 acute infectious conjunctivitis, 393 adherence, 40, 265, 720, 795 adiponectin, 253, 436, 660 adolescence, 830, 1225, 1332 adolescents, 293, 900, 1155, 1222 ADOPT, 1289 adult diabetes, 1186, 1247 adults, 445, 1165 African-Americans, 698 ageing, 1174 aids, 1110 albuminuria, 185, 502 alcohol, 795, 830 alcohol drinking, 690 aldose reductase, 367, 894 aldosterone synthase, 675 algorithms, 90 Anaemia, 839 angiotensin, 53 antihypertensives, 426 antimicrobials, 348 antioxidants, 258 anxiety, 917, 1106, 1110, 1381 aortic stiffness, 1201 arrhythmia, 207 arteries, 873 artificial β-cell, 90 artificial pancreas, 1 Asian diabetes, 1257 Asian Indians, 293, 537, 666, 845 association, 967 association study, 228, 1140 asymptomatic bacteriuria, 185 atherosclerosis, 228, 609, 808, 894, 955 ATP-sensitive potassium channel, 327 attention, 26, 32 automated insulin delivery, 1 autonomic neuropathy, 360, 574, 873 Avandamet, 1069

β-hydroxybutyrate, 278 β-thalassaemia major, 1327 bacteriological analysis, 99 basal insulin, 814 behavioural, 485 beliefs, 265 binge eating, 917 biomarkers, 1344 birth weight, 1301 birthweight, 1207 blind, 1110 blood glucose, 795, 1079 blood pressure, 94, 557, 780 BMI, 72 body composition, 384, 1357 body weight, 1079

caffeine, 574 calcitriol, 920 cancer, 1186 candidal carriage, 455 candidate gene, 367 cardiac events, 410 cardiovascular disearse, 1281 cardiovascular disease, 403, 1186 cardiovascular risk, 887 cardiovascular risk factors, 537 cardiovascular risk reduction, 780, 1117 care delivery, 377 carotid artery intima-media thickness, 609 carotid atherosclerosis, 617 carotid IMT, 845 carotid stenosis, 1377 case-control study, 393 CD14,72 central obesity, 469 cerebellar ataxia, 1136 cerebral blood flow, 398 cerebral oedema, 571 CGMS, 1124 chemokines, 156 childhood and adolescence, 1216 children, 86, 122, 293, 900, 1357 children and young people, 935 China, 1239 Chinese, 67 chronic pain, 1021 chronic wounds, 594 citations, 176 clamp, 246 clinical algorithm, 780 clinical studies, 360 coenzyme Q10, 1344 cognitive function, 26 cohort studies, 690 colour tissue Doppler, 1201 community health workers, 544 co-morbid depression, 445 co-morbidity, 1165 compartmental models, 21 congestive cardiac failure, 1313 continuous glucose sensing, 1

continuous subcutaneous infusion of insulin, 204

continuous subcutaneous insulin infusion, 90, 141

control algorithm, 1
controlled trials, 1050
coping, 1110
coronary artery calcification, 1192
coronary stenosis, 410
cost, 299, 1100
cost-effectiveness analysis, 164
co-stimulatory molecule, 1145
C-peptide, 1180
C-reactive protein, 763, 1192
CYP11B2, 675
cytokines, 156

death, 623 decision aids, 912 decision support technique, 912 decision support tools, 21 definition, 720 delivery of health care, 164 denaturing high-performance liquid chromatography, 681 depression, 917, 1110, 1165, 1381 diabetes, 21, 86, 128, 176, 189, 240, 377, 393, 410, 426, 436, 460, 485, 529, 574, 736, 763, 873, 982, 1008, 1106, 1130, 1239, 1252, 1344, 1370 diabetes education, 271, 544 diabetes mellitus, 148, 164, 171, 299, 323, 455, 623, 666, 955, 1117, 1339, 1377 diabetes mellitus Type 1, 156 diabetes mellitus Type 2, 419, 757 diabetes risk factors, 803 diabetes screening, 803 diabetes self-management, 271 diabetic complications, 185 diabetic foot, 99, 360, 649 diabetic foot ulcer, 341, 348 diabetic ketoacidosis, 278, 571 diabetic nephropathy, 331, 367, 675, 681, 1037 diabetic neuropathy, 1016, 1021 diabetic pregnancy, 223 diabetic retinopathy, 60, 643, 867, 1029, 1106 diagnosis, 341, 649, 982, 1257 diagnostic criteria, 1319 diet, 795, 1225 dietary adherence, 788 dietary carbohydrate, 15 digital non-mydriatic photography, 867 digital retinal screening, 629 drug utilization, 1117 dual-energy X-ray absorptiometry scanning, 384 duplex ultrasonography, 1377

early onset diabetes, 1136 eating behaviour, 788 echocardiography, 1201 economics, 1100 education, 122, 935 educational interventions, 485 effectiveness, 1100 efficacy, 246 electrolytes, 1124 endothelial dysfunction, 258, 398 endothelium, 873, 1350 end-stage renal disease, 1364 epidemiological model, 189 epidemiology, 148, 313, 857 epidemiology prospective studies, 690 erectile dysfunction, 198, 873 ergotamine, 574 ER Stress, 216 erythropoeitin, 839 erythropoieten, 574 ethnicity, 77, 94, 1233 euglycaemic glucose clamp, 522 exenatide, 240 exercise, 795 expectations, 1003 extrapyramidal signs, 1136

familial, 331
familial inheritance, 834
family average income, 1239
family history, 1233
fasting glucose, 1151, 1319
fasting glycaemia, 1327
fasting plasma glucose, 990
fetal programming, 1213
first hospital admission, 1261
fludrocortisone, 574
focus groups, 1222
folate, 529
follow-up study, 1261

GAD antibody, 211 gender, 907 gene-environment interactions, 907 gene mutation, 67 general practice, 788, 803, 887, 996 General Practice Research Database, 516 genetic association, 1093 genetic association studies, 419 genetic polymorphism, 1307 genetics, 228, 1037, 1140, 1257, 1295 genetics of Type 2 diabetes, 685 genotyping, 419 geographical distribution, 857 Germany, 299 gestational, 460 gestational diabetes, 306, 565, 1213, 1319 gestational diabetes mellitus, 313 ghrelin, 685 glargine, 46, 743 glibenclamide, 134, 327 gliclazide, 246, 757 glomerular filtration, 715 glomerular filtration rate, 1057 glomerulopathy, 715 glucocorticoids, 1281 glucodynamic, 510 glucose, 1025 glucose control, 90



glucose dependent, 240

glucose intolerance, 1174

glucose metabolism, 1307

glucose monitoring, 90

glucose sensors, 21

glucose tolerance, 306, 907, 1061, 1327

glucose tolerance test, 982

glutamic acid decarboxylase antibodies, 834

glycaemic control, 207, 557, 830, 1050, 1069, 1216, 1225, 1247, 1381

glycated haemoglobin, 944

graft vs. host disease, 436

Graves' disease, 211

growth factors, 594

guideline, 460, 579

haemoglobin A_{1c}, 1289

HbA_{1c}, 40, 285, 757, 900, 990, 1151, 1357

HbA_{1c} levels, 1050

HbA_{1c} targets, 1069

health care delivery, 122

health-care evaluation mechanisms, 912

health insurance, 299

health policy, 1247

health research impact, 176

heart-rate monitoring, 360

hemoxygenase-1, 666

hepatocyte growth factor, 617

hepatocyte nuclear factor-1α, 1295

high fat dietl insulin resistance, 1061

hippocampus, 32

HNF-1β, 1301

HOMA-IR index, 654

homeostasis model assessment, 1327

homocysteine, 529, 808, 1192, 1350

hormone replacement therapy, 763

hospital settings, 1106

hospitalization, 377

hyperglycaemia, 134

hyperinsulinaemia, 77

hypertension, 1130

hypoglycaemia, 26, 141, 729, 750, 1155

hypoglycaemia awareness, 750

IGT, 845

IL-18, 211, 235

impaired fasting glucose, 148, 803

impaired fasting glycaemia, 1130

impaired glucose tolerance, 148, 565, 609, 1025, 1130

IMT of the carotid artery, 228

incidence, 857, 1364

incretin, 240

Indian and Pakistani, 1003

infant growth, 1207

infection, 341, 348

inflammation, 763, 974

inhaled insulin, 510

inpatient bed occupancy, 1008

insulin, 879, 1025

insulin allergy, 204

insulin analogue, 522

insulin analogues, 285, 743, 879

insulin aspart, 729

insulin-dependent diabetes, 698

insulin detemir, 522, 729

insulin glargine, 46, 285, 736, 814, 879

insulin-like growth factor-1, 814

insulin-like growth factor binding protein 1, 814

insulin pump, 1

insulin pump therapy, 86, 900

insulin resistance, 94, 223, 306, 469, 510, 537, 654, 1307, 1357

insulin sensitivity, 384

insulin therapy, 176, 750, 879, 1155, 1216

insulin-treated adults, 271

intelligence, 26

intercellular adhesion molecule 1, 643, 1093

intermittent claudication, 327

International Diabetes Federation (IDF), 469

Internet, 1233

intervention, 113

intramuscular triglyceride, 1061

islet antibodies, 1180

islet autoantibodies, 67

ketosis, 1124

kidney disease, 502

Koreans, 198

lactic acidosis, 432

laser treatment, 60, 1106

latent autoimmune diabetes in adults, 834

lay health workers, 544

leptin, 660

Leu72Met, 685

lifecourse, 821

lifestyle, 720

linkworker, 1003

lipid metabolism, 907

lipids, 15, 94, 557, 1029

lipodystrophy, 436

lipo-prostaglandin E₁, 1339

lipoproteins, 768, 955

lispro, 743

low-density lipoproteins, 808

low-fat diet, 384

macroangiopathy, 894

macrosomia, 460

magnesium supplementation, 1050

magnetic resonance imaging, 32

management, 1252

Maori, 1313

maternal glucose, 1207

matrix metalloproteinases, 594

maturity-onset diabetes of the young 3 mutation, 1295

mean plasma glucose, 1151

measurement, 720

medication compliance, 265

memory, 32

meta-analysis, 1050

metabolic control, 113
metabolic factors, 1016
metabolic syndrome, 403, 441, 469, 845, 996, 1192, 1281
metformin, 128, 223, 318, 323, 432, 757, 1069, 1079
methods, 912
microalbuminuria, 426, 1057
microvascular complications, 367
microvascular disease, 360
microvolt T-wave alternans, 207
midodrine, 574
MODY, 1257

mortality rates, 698 MTHFR, 529 multicomponent, 485 multiple daily injections, 141 myocardial infarction, 974, 1313, 1370

myocardial perfusion imaging, 410

mortality, 516, 698, 1186, 1313

NADH oxidase, 1037 NADPH oxidase, 666 nateglinide, 757 nationwide study, 1261 natural history, 1021 needle puncture, 99 neighbourhood deprivation, 313 neonatal diabetes, 1301 neonatal morbidity, 318 nephropathy, 502, 1057, 1093 new definition, 469 nicotinamide, 920 nitric oxide, 398, 594 nitric oxide synthase, 398 non-alcoholic fatty liver disease, 403 non-HDL-cholesterol, 1029 normal glucose tolerance, 887 northern Chinese, 1085 NPH insulin, 814 nuclear magnetic resonance, 955 nurse-led clinics, 780

obesity, 15, 94, 128, 441, 565, 907 obstetrics, 481 octreotide, 574 oestrogens, 768 offspring, 565 oral agents, 40 oral candidosis, 455 oral glucose-lowering drugs, 736 oral glucose tolerance test, 654, 967 ORP150, 216 osteomyelitis, 99, 649 outcome, 1100 overprotection, 271 overweight, 1079 oxidative damage, 808 oxidative stress, 258, 666, 974, 1344, 1350

paediatrics, 1257 pancreatic B-cell function, 1180 pancreatic development, 1301
pancreatic venous drainage, 654
parents, 1222
partners, 271
patient-centred care, 944
patient participation, 164
patient symptoms, 60
PD-1, 1145
peripheral vascular disease, 327
peroxisome proliferator-activated receptor γ co-activator-1, 1085
pharmacodynamics, 522
pharmacodynetic, 510
pharmacokinetic, 510
pharmacokinetics, 323
phenotype, 1289
phosphoenolpyruvate carboxykinase, 419

physical activity, 1025 pioglitazone, 246, 436, 537 plasminogen activator inhibitor type 1, 887 platelets, 134 polaroid non-mydriatic phtotography, 867 polymorphism, 72, 211, 235, 635, 643, 675, 685, 894, 1085

portal venous drainage, 654
postchallenge glucose, 1174
postchallenge hyperglycemia, 982
postprandial, 240, 768
postprandial glucose, 743, 990, 1151
postprandial lipoproteins, 258
postural hypotension, 574
PPAR delta, 1307
PPARGC1B, 635

PPARGC1B, 635
pre-diabetes, 156
preeclampsia, 318
pregnancy, 171, 306, 318, 323, 426, 460, 481, 1213
premature stroke, 1261
preterm, 426

prevalence, 148, 189, 198, 299, 441, 445, 982, 1165 primary care, 86, 516, 851, 1117 primary prevention, 1233 prognosis, 623 promoter, 235

proteinuria, 715 psychiatric morbidity, 113 psychological support, 917 psychology, 935 psychosocial, 485 pulmonary oedema, 571

qualitative methods, 1222 quality assurance, 629 quality of care, 851 quality of life, 60, 141 QUICKI index, 654

race, 1289
randomized controlled trial, 736, 944
red wine, 974
regulatory T cell, 1145
renal failure, 432
repaglinide, 134

DM

research evaluation, 176
resistin, 660
rest homes, 1252
retinal pigment degeneration, 1136
reversibility, 1016
risk, 393
risk factor, 313
risk factors, 198, 698, 750, 1377
risk score, 996, 1370
rural, 122

safety, 246 SARS, 623 screening, 867, 996, 1319 self-efficacy, 1332 self-management, 544 self-monitor blood glucose, 1247 sensitivity, 629 sequence variants, 681 serum, 156 service users, 917 services, 1003 sex hormone-binding globulin, 306 sick day management, 278 silent myocardial ischaemia, 775, 1186 simultaneous pancreas-kidney transplantation, 654 single nucleotide polymorphism, 967, 1093 single-strand conformation polymorphism, 643 smoking, 510 social class, 313 social consequences, 821 social support, 1332 socio-economic status, 1239 South Asians, 845 South Indians, 1029 specialist care, 1117 specialist clinics, 851 specialist nurse, 1008 specificity, 629 spinal cord infarction, 571 standardized test meal, 743 steroid, 623 stress hyperglycaemia, 1370 stroke, 529, 894 structured group education, 944

temporal trends, 1364 text message, 1332 thiazolidinedione, 253

subclinical disease, 955

sulphonylureas, 128

sudden hearing loss, 1339

systematic review, 341, 348, 609, 821

systemic lupus erythematosus, 1145

timing, 46 tissue-type plasminogen activator, 887 TNF-0, 660 tocopherol, 1344 total prevalence, 189 treatment, 720, 1021 trend, 857 triglyceride, 72, 635 triglyceride-rich lipoproteins, 258 triglycerides, 1029 tumour necrosis factor-α, 253 Type 1 diabetes, 26, 32, 46, 53, 113, 122, 235, 278, 285, 384, 445, 481, 557, 675, 681, 698, 729, 808, 834, 857, 879, 920, 935, 1079, 1124, 1145, 1155, 1201, 1216, 1222, 1225, 1261, 1364, Type 1 diabetes mellitus, 141, 571, 821, 1093, 1332, 1350 Type 1 diabetic children, 660 Type 1 DM, 216 Type 1B diabetes mellitus, 67 Type 2 diabetes, 15, 40, 185, 204, 207, 228, 246, 265, 293, 318, 398, 403, 432, 481, 502, 516, 579, 609, 750, 775, 788, 834, 845, 944, 990, 996, 1003, 1025, 1069, 1100, 1140, 1192, 1233, 1289, 1313, 1357, 1364 Type 2 diabetes mellitus, 72, 134, 198, 253, 327, 617, 635, 690, 768, 839, 967, 1085, 1165

ulcer swabbing, 99 undiagnosed diabetes, 803 university students, 1155 urban Nepal, 1130 urine ketones, 278 utility, 1100

Type 2 diabetes susceptibility, 1295

variation in care, 377
vascular complications, 1100
vascular disease, 1350
vascular dysfunction, 537
vascular endothelium, 53
vibration perception threshold, 1016
visfatin, 967
visual impairment, 60

weight, 900 weight gain, 557 weight loss, 15 within-person variation, 729 women, 77 women's health, 763 wound healing, 594

xylosyltransferase I, 681

young adults, 293



